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ABSTRACT
Drug Repurposing for COVID-19 Using Molecular Docking Tools
by Deniz Yasar Oztas
Since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly contagious and
mortal, finding a treatment is time critical. Drug repurposing is probably the quickest and safest
approach in our arsenal. However, testing every drug in a brute force manner would require a lot
of resources, and a more sophisticated method is required to filter possible candidates. Since
several molecules have already been shown to be effective against SARS-CoV-2 in wet-lab
experiments, choosing drugs with similar characteristics would increase our chances of success.
In this study, we compare the molecular docking results of FDA-approved drugs from the ZINC
database against the molecules with positive experimental results. AutoDock Vina was used to
dock the molecules against the SARS-CoV-2 spike receptor bound to the ACE2 receptor (6M0J).
Results were pre-filtered to 50 candidates according to their binding affinities and the 10 most
promising molecules that have similar interactions with the experimental drugs were identified.
Then, the 10 molecules were docked against B.1.1.7, B.1.351, and P.1 variants, and their inhibition
potentials were discussed. According to the results, we conclude that some molecules that inhibit
the wild type also have the potential to inhibit the variants as well. However, further experimental
and clinical studies are needed.
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Chapter 1 - An Overview of SARS-CoV-2
1.1 Introduction
2020 was a year of great financial distress, product shortages, stay-home orders, panic across
widespread populations and possibly lasting changes in the way people conduct their lives. The
reason for these events was a virus which first appeared in Wuhan, China in late 2019. Everything
started as a local outbreak and quickly spread to the whole world. The virus is highly infectious
and mainly spreads through contact/droplet transmission. It can cause pneumonia, Acute
Respiratory Distress Syndrome (ARDS), and other complications (Guan, Ni et al. 2020). Its origins
remain unknown. However, due to its genetic similarities to the Severe acute respiratory syndrome
(SARS), the virus was named as SARS-CoV-2 (Petersen, Koopmans et al. 2020). On March 11th,
the World Health Organization (WHO) declared the disease a global pandemic and a global effort
to battle the virus followed.
In the year following the WHO declaration, several vaccines were developed, got approvals from
regulators around the world and started to be administered (Forni and Mantovani 2021). However,
as of right now, there is still no official treatment for the infected patients. Since a large portion of
the global population currently does not have access to the vaccinations and the mutations the virus
is undergoing, reaching herd immunity might be an elusive goal. Therefore, finding a treatment is
still an important and time-critical task.

1.2 Coronaviruses
Coronaviruses are a large family of viruses which belong to the Nidovirales. Nidovirales is an
order of single-stranded, positive-strand RNA viruses with envelopes. Nidovirales order includes
four families which are Coronaviridae, Mesoniviridae, Roniviridae, and Arteriviridae (Enjuanes,
Gorbalenya et al. 2008). The Coronavirinae is one of two subfamilies of the Coronaviridae family,
1

and it is divided into four genera which are alpha, beta, gamma, and delta coronaviruses (Payne
2017). According to the genomic characterization, while the alpha and beta coronaviruses probably
originated from bats and rodents, delta and gamma coronaviruses originated from avian species.
Coronaviruses can infect various species such as camels, cats, and bats. They can cause various
types of diseases such as respiratory, hepatic, and neurological. They can jump from animal species
to humans, albeit usually through an intermediate species (Campana, Parisi et al. 2020). So far,
seven coronaviruses that can infect humans were discovered. These seven coronaviruses are
known to belong to either alpha or beta coronaviruses genera (Ye, Yuan et al. 2020). Of the seven,
three have caused lethal outbreaks: SARS-CoV, MERS-CoV, and SARS-CoV-2. While the first
two were zoonotic outbreaks, the origin of the third outbreak remains unknown. There is some
evidence of a zoonotic link, but the evidence is not conclusive (Campana, Parisi et al. 2020).
SARS-CoV was first seen 2003 and had a 9% mortality rate (Sørensen, Sørensen et al. 2006). It
bound to angiotensin-converting enzyme 2 (ACE2) on the cell membrane and caused pneumonia,
which led to acute respiratory distress syndrome (ARDS). It spread to multiple countries but was
contained quickly. A total of 8098 people got sick, and 774 of these people died (Hui and Zumla
2019).
MERS-CoV, or Middle East respiratory syndrome, was first seen in 2012 and had a 35% mortality
rate (Alsolamy and Arabi 2015). Unlike SARS-CoV, MERS-CoV bound to Dipeptidyl peptidase4 (DPP4) on the cell membrane and caused ARDS as well. It is a rarely seen disease that does not
spread quickly. So far, a total of 2519 people got sick, and 866 died (Organization 2019).
SARS-CoV-2 is similar to SARS-CoV. It was first seen in 2019 and has a 3.4% mortality rate
worldwide (Roussel, Giraud-Gatineau et al. 2020). It also binds to angiotensin-converting enzyme
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2 (ACE2) on the cell membrane and, like the other two viruses, causes pneumonia, which leads to
acute respiratory distress syndrome (ARDS). It is much more contagious and, at the time of
writing, was not contained. So far, a total of 141 million people got sick, and 3.01 million people
died.

1.3 Structure of Coronavirus
Coronaviruses have highly conserved genomic organization, and the genome of these viruses
encode structural proteins, non-structural proteins, and accessory proteins (Artika, Dewantari et
al. 2020). Coronaviruses have a single-stranded RNA genome which is very large (up to 33.5 kb
genomes) (Fehr and Perlman 2015). The genome is structured like an mRNA; it has a 5′ cap and a
3′ poly (A) tail. Therefore, it can utilize the host cell for translation of its replicase gene (up to
20kb), which encodes two polyproteins that get cleaved into the non-structural proteins (nsps).
These nsps play various important roles like blocking interferons, host immune proteins that the
cell produces as an immune response (Kamitani, Narayanan et al. 2006, Kamitani, Huang et al.
2009). They also facilitate the viral RNA replication and sub-genomic transcription of RNA, which
creates the structural proteins. Structural proteins form the final virions and facilitate the exit from
the host cell. They are necessary to protect the genome and to infect the next host cell (Tanaka,
Kamitani et al. 2012). The third group of proteins, accessory proteins, are also produced during
the infection (Zhao, Jha et al. 2012). These proteins do not play a part in the replication but are
required for viral pathogenesis.
Coronaviruses are spherical viruses, and they are approximately 125 nm in diameter. They are
composed of four main structural proteins, membrane (M), envelope (E), nucleocapsid (N), and
spike (S) proteins (Fehr and Perlman 2015). All of these proteins are encoded within the 3’ end of
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the viral genome. Because of the spike glycoproteins on its envelope, under an electron
microscope, SARS-COV-2 looks like a crown. It is demonstrated in Figure 1.

Figure 1. Illustration of the Structure of SARS-CoV-2.

The Membrane protein is approximately 25–30 kDa and has three transmembrane domains
(Armstrong, Niemann et al. 1984). It is the most expressed structural molecule and gives the
viruses their shapes. The M protein has an N-terminal glycosylated ectodomain and a C-terminal
endodomain. M protein interacts with all the other structural proteins and organizes the assembly
process. According to the studies, it is a functionally dimeric protein. It is suggested that M protein
can take two conformations. Membrane curvature is regulated to play different roles during
different assembly stages. It captures other structural proteins and gets the virion ready for budding
(Neuman, Kiss et al. 2011).
The Envelope protein is approximately 8–12 kDa (Schoeman and Fielding 2019). It is expressed
in high quantities, but only a small portion is found in the virions. It has an N-terminal ectodomain
and a C-terminal endodomain and also has ion channel activity. This ion channel activity is
required for pathogenesis (Nieto-Torres, DeDiego et al. 2014). The E protein is a small

4

transmembrane protein and is responsible for the assembly & release of the virus. E protein is
heavily involved in the budding process (Li, Surya et al. 2014).
The Nucleocapsid protein is approximately 45 kDa (Fan, Ooi et al. 2005). It has an N-terminal
domain and a C-terminal domain, and both domains can individually bind to RNA through
different mechanisms. However, for optimal binding, contributions from both are required. N
protein is heavily phosphorylated (Stohlman and Lai 1979). Phosphorylation is suggested to help
increase the N proteins’ affinity towards the viral RNA. N protein binds to the viral RNA genome
and protects it by forming a shell around it (Hurst, Koetzner et al. 2013, Kuo and Masters 2013).
During the assembly phase, N protein binds to the C-terminal RNA binding domain, M protein,
nsp3, and a non-structural protein from the replicase complex. It ties the viral RNA genome to the
replicase–transcriptase complex (RTC), and then helps package the genome into the viral
envelope.
The last piece, S protein, is approximately 150 kDa (Beniac, Andonov et al. 2006). It distinctively
exists on the surface of the virus. The S protein consists of a large ectodomain, a small endodomain,
and a single transmembrane anchor (Wang, Grunewald et al. 2020). The ectodomain consists of
two subunits, S1 and S2. During the infection phase, S protein is cleaved by a host furin-like
protease, a cell surface protein, into S1 and S2. S1 subunit binds to the receptor, and S2 subunit
handles the membrane fusion, which leads to the viral fusion and entry into the host cell (Bosch,
Van der Zee et al. 2003).
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1.4 Entering Mechanism of SARS-CoV-2
Understanding the entry mechanism of the SARS-CoV-2 into human cells is vital for designing
therapies against it. Like all coronaviruses, SARS-CoV-2 enters the cells via the S protein (Shang,
Wan et al. 2020). The mechanism of entry of SARS-CoV-2 is demonstrated in Figure 2.

Figure 2. Illustration of the entry mechanism of SARS-CoV-2

The infection starts with the S1 subunit of the trimeric spike protein binding to the ACE2 receptor,
which is a type I membrane protein expressed in lungs, heart, kidneys, and intestine cell surfaces
(Hamming, Timens et al. 2004). Unlike other SARS viruses, The SARS-CoV-2 spike protein has
a proprotein convertase (PPC) cleavage site, which separates S1 and S2 (Walls, Park et al. 2020).
The human type I transmembrane protein furin and transmembrane serine protease 2 (TMPRSS2)
on the host cell membrane cleave the S protein (Bestle, Heindl et al. 2020). The resulting S1
subunit dissociates, and S2 subunit transitions to a post-fusion conformation which helps fuse the
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host cell and viral membranes. The post-fusion S2 domain, which drives this process, has a peptide
region that can be activated by receptor recognition; and once activated it can interact with the host
cell membrane (Xiu, Dick et al. 2020).

1.5 Receptor Binding Domain
The area on the SARS-CoV-2 that binds to the ACE2 inhibitor is called RBD, receptor-binding
domain. This area and its interactions with ACE2 were studied thoroughly using X-ray
crystallography and cryo-electron microscopy (cryo-EM) (Song, Gui et al. 2018). There are
multiple 3D structures in the Protein Data Bank, which illustrate this region. Some of the
commonly used ones are: PDB: 6M17, PDB: 6M0J, PDB: 6VW1, PDB: 6LZG. While the 6M17,
6M0J, 6VW1, and 6LZG structures represent the crystal structure of the spike protein that is bound
to ACE2, 6XEY represents the crystal structure of the SARS-CoV-2 spike glycoprotein that is
bound to antibodies (Lan, Ge et al. 2020, Liu, Wang et al. 2020, Shang, Ye et al. 2020, Wang,
Zhang et al. 2020, Yan, Zhang et al. 2020).
According to the studies, spike protein and ACE2 make a significant number of hydrogen and
hydrophobic bonds. It has been shown that Lys417, Gly446, Tyr449, Tyr453, Leu455, Phe456,
Gln474, Ala475, Gly476, Phe486, Asn487, Tyr489, Gln493, Gly496, Gln498, Thr500, Asn501,
Gly502, and Tyr505 are the binding residues of SARS-CoV-2, which form hydrogen bonds. On
the other side, Ser19, Gln24, Thr27, Phe28, Asp30, Lys31, His34, Glu35, Glu37, Asp38, Tyr41,
Gln42, Leu45, Leu79, Met82, Tyr83, Asn330, Lys353, Gly354, Asp355, Arg357, and Arg393 are
the contact residues for ACE2 (Shang, Ye et al. 2020, Yan, Zhang et al. 2020).
SARS-CoV-2 binds to the ACE2 receptor with a higher affinity than SARS-CoV (Shang, Ye et al.
2020). However, it also has defenses against the host immune system. Spike protein has two
conformations: laying down and standing up. Unlike SARS-CoV, it spends most of its time in the
7

down setting, which helps it evade the immune response. However, certain host proteases cause it
to adopt the standing up conformation, and in this form, it can identify the ACE2 receptor and bind
to it with high affinity (Campana, Parisi et al. 2020, Walls, Park et al. 2020).

1.6 Diagnosis and Treatment
For most patients, diagnosis and treatment of SARS-CoV-2 are unnecessary. Patients get common
cold symptoms like fever, cough, fatigue, and their immune systems handle the infection without
any major incident. Unfortunately, some of the other patients, especially older patients and patients
with underlying conditions, get severe symptoms like shortage of breath, chest pains, and
confusion, which can lead to hospitalizations and even death. Since the virus is highly infectious,
it can easily infect large populations and cause the health services to get overwhelmed by the
number of patients with severe symptoms. Therefore, early diagnosis of disease and isolation of
the patients from the rest of the population is critical.
Since the symptoms of SARS-CoV-2 show high variance and can be mixed up with other diseases
such as flu; radiological imaging is required to diagnose the disease with high prediction rates
(Hosseiny, Kooraki et al. 2020). Currently, there are multiple classes of tests available for SARSCoV-2 screening: serological tests (ex: Elisa) that detect antibodies in the bloodstream, molecular
tests (ex: RT-PCR) that isolate and amplify certain parts of the virulent RNA, and nanotechnologybased tests that use nanoparticles to bind to the antigens (Emery, Erdman et al. 2004, Beavis,
Matushek et al. 2020, Singhal, Gupta et al. 2020). Of these various methods, PCR has become the
most used one (Waller, Kaur et al. 2020). However, serologic assays are also important for
collecting data for epidemiological studies.
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Currently, the best way to combat SARS-CoV-2 is prevention. Unfortunately, isolation of sick
patients, social distancing, and better hygiene have not been enough to contain the disease, and
especially with the new variants of the virus showing up, herd immunity might be hard to achieve.
Therefore, there is a global campaign to vaccinate people. There are currently multiple vaccines
in the market, and more are in the pipeline. These vaccines belong to 5 distinct categories: mRNA
vaccines (Biontech and Moderna), replication-defective viral vector vaccines (AstraZeneca, JNJ),
inactivated pathogen vaccines (Sinovac), protein subunit vaccines (Novovax) and virus like
particle vaccines (Medicago) (Kyriakidis, López-Cortés et al. 2021). Each of these families has
cons and pros, but none are 100% effective against all variants, and there is not enough supply of
them for the entire population.
Since prevention goes only so far, treatments are required to treat patients with severe symptoms.
To this date, no official therapeutics that were specifically designed for SARS-CoV-2 have been
approved. There are currently multiple drug therapies being used against the virus. However, these
act as supplemental aid that relieves the symptoms and shortens the recovery time. Remdesivir,
Lopinavir - Ritonavir, Favipiravir, Ribavirin are some of the commonly used drugs. Remdesivir
and Favipiravir are RNA polymerase inhibitors (Du and Chen 2020, Jorgensen, Kebriaei et al.
2020). Lopinavir - Ritonavir are protease inhibitors (Horby, Mafham et al. 2020). And Ribavirin
is a guanosine analog (Thomas, Ghany et al. 2012). These are mostly anti-viral drugs that are
designed to treat other viral diseases. However, since they interfere with different stages of the
viral replication, they limit the symptoms and help the recovery time.
Another group of commonly used drugs is immunosuppressants such as interferon β-1b and
Interleukin-6 Inhibitors (Russell, Moss et al. 2020). These are used to treat the cytokine storm that
is caused by the host's immune response. When a host's innate immune system gets activated, it
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causes the production of cytokines, pro-inflammatory molecules. Under normal circumstances,
this is the normal response to a viral infection. However, SARS-CoV-2 can cause an overreaction,
where the system goes into a positive feedback loop and creates too much cytokines. This
exaggerated immune response can cause tissue damage and cause ARDS (Ragab, Salah Eldin et
al. 2020). This group of drugs are used to limit the host’s immune response and avoid organ failure.
The last option currently being used is treatment with plasma from recovered SARS-CoV-2
patients (Duan, Liu et al. 2020). Once a patient recovers from the disease, his blood carries
antibodies that were used to battle the infection. These antibodies can be harvested and given to
another patient who has severe symptoms. Although this method is the most effective amongst all
the treatments, it is not scalable.
Since no highly effective and scalable treatment exists yet, new drug candidates need to be found
and studied. However, a lead drug takes a very long time to develop. Therefore, strategies like
repurposing existing drugs can be used. To treat the disease instead of its symptoms, the entry of
the virus into the cells can be blocked. This can be managed by interfering with the ACE2-RDB
interaction.
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Chapter 2 - Computer Aided Drug Repurposing and Its
Applications for SARS-CoV-2
2.1 Introduction
Our bodies are extremely complex machines. At any given time, many different molecules interact
with each other and help the system keep functioning. When an external factor, such as SARSCoV-2, interferes with the system, finding a targeted remedy is no small task. The possible drugs
space is infinitely large and when a molecule is being considered as a treatment, its interactions
with the other molecules in the system have to be safe for the host. There are some guidelines that
rely on heuristics, such as Lipinski's rule of five, to make the process manageable (Lipinski,
Lombardo et al. 1997). But even with the restricted input space and simplified constraints, in order
to discover a successful treatment, a lot of experiments need to be performed. Since wet-lab
experiments are both costly and time-consuming, filtering out improbable candidates would
increase efficiency and decrease development time. This is why computational methods are being
developed and widely used.
As a first step, computational methods can be used in conjunction with bioinformatics to identify
disease-causing protein sequences and predict their structures. Then these structures can be
computationally analyzed according to their structural and molecular properties for druggable
pockets, where an agent can bind with high affinity. After the druggability of the target is verified,
target drug molecules can be screened, and promising ones can be filtered. Later these promising
drug molecules can be further optimized and filtered using structure-based optimizations and
Quantitative Structure-Activity Relationship (QSAR) models (Kwon, Bae et al. 2019). Once the
drug molecule is optimized, its toxicity, pharmacokinetics, and polypharmacology can be studied.
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There are three major computer-aided drug design strategies: ligand-based, system-based, and
structure-based.
A ligand is a molecule which binds to a biomolecule and causes a biochemical change (Mobley
and Dill 2009). Ligands that trigger the receptor and cause a biological response are called agonists
and ligands which block the receptor are called antagonists (Berg and Clarke 2018). In the ligandbased approach the chemical properties and the structure of a compound is known (Aparoy, Kumar
Reddy et al. 2012). This knowledge is then used to find similar compounds that bind to a target
macromolecule or to design/identify other molecules that have enhanced properties or to identify
target receptors. In the first two approaches, chemical similarity is used, and similar ligands are
considered. The similarity is usually measured by using features called fingerprints. Fingerprints
are vectors that define a molecule in terms of paths or substructures. Once molecules are
quantified, distance metrics, such as the Tanimoto index, can be used to quantify the similarity
between them. Using this approach, similar molecules which might be more favorable could be
identified (Lo, Gui et al. 2016). On the other hand, in the third approach, biochemical properties
of ligands, such as MolMR, MolLogP, TPSA, can be used to predict their affinities against a library
of proteins (Boyles, Deane et al. 2020).
In the system-based approach, a more holistic view is taken. Interactions of the proteins, genomes,
pathways, and their responses to certain chemical signals are taken into account (Draghici, Khatri
et al. 2007). Computational methods are used to find insights on the systems level, and instead of
a minimalist approach that concentrates on molecule pairs, a unified approach is taken. Interactions
are analyzed as a network of events and drugs are targeted to modulate that network. In this
approach certain drugs that have certain functions can be used to treat other diseases where similar
functions are still effective.
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In the structure-based approach, the structure of the target protein is known (Batool, Ahmad et al.
2019). This structure may be identified in the wet lab using techniques like multi-dimensional
nuclear magnetic resonance (NMR) and X-Ray diffraction technique or it may be a product of
molecular modeling and simulations. The first step in this approach is finding a potential receptor
site. Target sites usually have certain features like having potential hydrogen donors and acceptors.
They can be ridges or pockets on the surface, which act as assembly, communication, or active
sites. These sites are identified either through wet-lab experiments, by using homology models or
by identifying sites that would interact with functional groups that drug-like molecules usually
carry (Laurie and Jackson 2005). The next step is looking for hits, and it can be done in two
different ways: de-novo design and virtual screening.
In the de novo method, molecules are built from scratch according to the properties of the binding
site (Lin, Li et al. 2020). Atoms or frequently used molecule fragments such as rings can be stitched
together to build molecules that interact well with the binding domain (Reutlinger, Rodrigues et
al. 2014). One or multiple reference molecules can also be used as a point, and their fragments can
be linked to other scaffolds. De novo drug design is an area where machine learning methods like
VAE, GAN, and genetic algorithms can be used (Mouchlis, Afantitis et al. 2021).
In the second method, virtual screening, a library of molecules are tested against the structure of
interest (Lyne 2002). Ligands and the structure interact due to the intermolecular forces between
them and can form hydrogen, ionic, hydrophobic or Van Der Waals bonds. The measure of the
strength of the interactions between the ligand and the structure is called binding affinity, and it is
used to compare and rank the ligands (Huang, Bonnichon et al. 2017). A lower binding affinity
means a stronger attraction and a higher binding affinity means a weaker attraction. Binding
affinity is usually expressed by the equilibrium dissociation constant (KD).
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KD is calculated by

𝐾𝐾𝐾𝐾 =

[𝐿𝐿][𝑃𝑃]
[𝐿𝐿𝐿𝐿]

where [L] is the molar concentration of the ligand, [P] is the molar concentration of the protein,
and [LP] is the molar concentration of the complex (Kastritis and Bonvin 2013). In order to have
a sense of the binding affinity between the molecule and the structure, how they are positioned
against each other needs to be known. Same structure and ligand can have very different affinities
in different geometries. This is where molecular docking is used.
Molecular docking is a computational method that predicts the most likely pose and location a
ligand would take against a structure. Molecular docking tools create thousands of different ligand
conformations at the target protein's active site, rank them with a scoring function, and try to find
the pose with the lowest binding energy. A low and negative binding energy means that when the
ligand binds to the structure, energy is released. This would decrease the total energy of the system
and make the system more stable, hence more likely. A simple illustration of molecular docking
can be found in Figure 3.
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Figure 3. Illustration of basic procedure for molecular docking.

Using large and diverse molecule libraries for screening is a common practice in drug studies
(Kodadek 2011). In virtual screening, compounds from databases, such as ZINC, are docked
methodically against the target structure and promising ones are identified (Kodadek 2011). These
databases are specially curated for virtual screening and contain a significant number of
commercial and experimental molecules. In this sense, virtual screening can be considered as the
in silico version of high-throughput screening (HTS) (Stahura and Bajorath 2004). However, it is
a faster and more cost-effective method.
When promising ligands are identified, and their binding modes are known, more insights can be
derived about the molecule and how it interacts with ligands. This knowledge can be used to
optimize the ligands by modifying them, or even to design new ones. A larger database would
enable more diverse candidates and greater insight.
However, the docking method is not without challenges. Since there are too many degrees of
freedom in the system, creating a very realistic simulation would be computationally demanding
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(Adcock and McCammon 2006). Therefore, simple approximations, such as treating the protein
and ligand as separate rigid objects, are used to make the simulations more manageable. This, of
course, comes at an accuracy cost (Perez and Tvaroška 2014). There are many molecular docking
programs, and they all use different algorithms, assumptions, and approximations. So, they all
have their advantages and disadvantages.

2.2 Molecular docking algorithms
In 1894 Fisher proposed that ligands interacted with receptors that had geometric matching
structures (Fischer 1894). He used an analogy to describe his thesis: lock and key (Koshland Jr
1958). This model was too simplistic, and in 1958 Koshland proposed an alternative: Induced Fit
Theory (Ohue, Shimoda et al. 2014). In this model, both ligands and proteins were flexible and
changed shapes after their interaction for a better fit.
There are two types of molecular docking that follow these two models: rigid-body docking and
flexible docking. Rigid-body docking is usually done for pre-screening and to identify binding
sites. It does not consider the flexibility of the agents. Therefore, it is fast but not accurate. The old
versions of DOCK and FLOG softwares use this methodology.
On the other hand, in flexible docking not only translational and rotational axes are considered,
but also possible conformations of all agents are included in the simulation as well. This causes a
significantly larger search space. Therefore, flexible docking is more computationally intense, but
more accurate. There are many variants of these two approaches as well. Most docking tools
assume that the ligand is flexible, and the receptor is rigid (Pagadala, Syed et al. 2017). Molecular
Dynamics (MD) simulations are better suited for modeling completely flexible ligands and
receptors. However, since molecular dynamics simulations are computationally expensive, some
semi-flexible methods were attempted (Salmaso and Moro 2018). For example, the Lennard-Jones
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8-4 potential in GOLD and smooth potential in AutoDock 3.0 belong to this class (Meng, Zhang
et al. 2011). These methods don’t have perfect flexibility, but they are computationally more
efficient than MD simulations.
Docking tools try to find stable conformations of the ligand-structure complex. To do that they use
search algorithms that go through the possible conformations space and try to converge on the
minimum energy setting. These can be categorized into two categories: systemic algorithms
(exhaustive search algorithms, fragment-based search algorithms) and stochastic algorithms
(genetic algorithms and Monte Carlo algorithms) (Sliwoski, Kothiwale et al. 2014).
Exhaustive search algorithms span the whole conformations space with set intervals and consider
every possible degree of freedom. However, if the possible conformation space is too large, certain
shortcuts can be taken to decrease the required computational power. For example, initially, a
lower resolution could be used to identify an area of interest, where a higher resolution search can
be continued. Grid-based searching is another option. After voxelization ligands and the protein
grids can be transformed with 3D FFT and scored using convolutions, which are computationally
more efficient (Ohue, Shimoda et al. 2014). Another strategy that is used to shrink down the search
space is using heuristics. Depending on the structure characteristics, certain areas could be picked
as low energy candidates. This strategy is employed by GLIDE (Friesner, Banks et al. 2004).
Fragment-based algorithms divide the ligand into smaller building blocks and form the final result
by using the results of the fragments. There are a couple of different fragment-based algorithms:
incremental construction, distance geometry, and shape matching.
Incremental construction (IC) separates the ligand into fragments and then starts to dock into the
target's active site (Rarey, Kramer et al. 1996). The first docked fragment is usually the largest one
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or has the most potential against the target. The first docked fragment can be considered as an
anchor, and the remaining fragments are added to this anchor incrementally. Therefore, this
method is also called the anchor and grow method. Since different poses are generated by
construction, this method can handle the flexibility of the ligands as well. IC is used in DOCK,
FLOG, and SLIDE (Kuntz, Blaney et al. 1982, Miller, Kearsley et al. 1994, Schnecke and Kuhn
2000).
Matching Algorithm is an approach that is based on molecular shapes (Fischer, Norel et al.
1993). This algorithm tries to maximize the overlap between areas that are derived from the
molecules using their molecular shape (& complements) and electrostatics properties. Although
Matching algorithms are fast, their accuracies are not the highest (Moitessier, Englebienne et al.
2008). They are often used in conjunction with other methods such as incremental construction
and FFT too. For example, DOCK algorithm matches spheres, which are derived from ligand
fragments, with the complement of the receptor and builds back the ligand to find the optimal pose
(Kuntz, Blaney et al. 1982). Matching Algorithms are also used in LibDock, and FLOG (Miller,
Kearsley et al. 1994, Diller and Merz Jr 2001)
Stochastic search algorithms use probability distribution functions to make random changes and
move in the direction of changes with positive results. Due to its stochastic nature, this strategy
has a better chance to avoid local minima. However, it also requires more computing power for a
wide-area search. Monte Carlo and genetic algorithms are the most commonly used stochastic
search algorithms.
Monte Carlo (MC) is a stochastic method that randomly modifies the ligand conformation (Hart
and Read 1992). MC method starts with a random initial pose of the ligand and scores this pose
according to a specific energy-based function. Then using a probabilistic approach, small changes
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are made to the pose, and the new pose is rescored. Poses with better scores are kept and poses
with worse scores are discarded with respect to the output of another probability function. This
operation continues till the target number of conformations are generated and the minimum energy
pose is found. Monte Carlo was used in earlier versions of AutoDock (Goodsell and Olson 1990).
Genetic algorithms (GA) is another stochastic method that tries to find the conformation with
global minimum energy (Jones, Willett et al. 1997). The idea comes from Darwin’s evolution
theory. Like the theory, there are mutations, mating, and crossovers in this method as well. The
current poses of the ligands and the receptors can be considered as chromosomes. In the same
manner, rotation, conformation, and translation parameters of the ligand can be considered as
genes. Chromosomes are stochastically modified, paired with other chromosomes, and go through
the crossover to produce offsprings. Then these offsprings are evaluated with a scoring function
and offsprings with better scores are retained for the next round. Genetic algorithms are used in
AutoDock and GOLD (Morris, Goodsell et al. 1998, Verdonk, Cole et al. 2003).

2.3 Scoring Functions
Docking is not only used to find the lowest energy poses of a ligand. It is also used to compare the
performances of different ligands during virtual screening. In order to be able to compare the
binding affinities of two different ligands a metric called scoring function is used. There are several
scoring functions that are used in different docking tools. Scoring functions are mathematical
approximation methods for estimating binding affinity. They usually depend on free energy
calculations. They need to be consistent and accurate for all types of ligands. Three basic types of
scoring functions are used for protein–ligand docking: force-field, empirical, and knowledgebased functions.
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Force field-based scoring functions use van der Waals interactions, electrostatic interactions, and
torsional forces to calculate the affinities (Huang, Kalyanaraman et al. 2006). Some of the terms
used in the function can be tuned with experimental data as well. DOCK force field score is
estimated by using the equation,

𝐸𝐸 = � �(
𝑖𝑖

𝑗𝑗

𝐴𝐴𝑖𝑖𝑖𝑖 𝐵𝐵𝑖𝑖𝑖𝑖
𝑞𝑞𝑖𝑖 𝑞𝑞𝑗𝑗
12 − 6 + 𝜀𝜀(𝑟𝑟 )𝑟𝑟 )
𝑟𝑟𝑖𝑖𝑖𝑖
𝑟𝑟𝑖𝑖𝑖𝑖
𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖

where i and j are atom indexes for the ligand and the protein, r stands for the distance between
atoms, A/B stands for van der Waals parameters, and q stands for atomic charges (Weiner,
Kollman et al. 1984). Force field-based scoring functions can utilize modern force fields like
CHARMM and Amber as well (Debroise, Shakhnovich et al. 2017). Force field-based scoring
functions do not consider solvation, and lose precision due to the lack of focus on the non-bond
interactions between far away atoms. Force field-based scoring is used by DOCK, Autodock and
GOLD (Meng, Shoichet et al. 1992, Jones, Willett et al. 1997, Morris, Goodsell et al. 1998).
Empirical based functions use different intermolecular interaction terms that are estimated by
multiple linear regression of binding energies from lab experiments (Liu and Wang 2015). A
typical empirical scoring function would look like this:

∆𝐺𝐺 = � 𝑊𝑊𝑖𝑖 . ∆𝐺𝐺𝑖𝑖
𝑖𝑖

where ∆Gi represents different energy terms such as VDW energy, electrostatics, hydrogen bond,
entropy, hydrophobicity. The corresponding weight coefficients are determined by empirical
methods. Binding affinities of a protein–ligand training set is fitted with three-dimensional
representations of known structures (Sotriffer, Sanschagrin et al. 2008). The empirical-based
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functions are generally faster than force field-based scoring functions (Jain 1996). Empirical
scoring is used by Glide, ChemScore, and X-Score (Wang, Lai et al. 2002, Verdonk, Cole et al.
2003, Halgren, Murphy et al. 2004).
Knowledge-based scoring functions are also statistics-based scoring functions. They use statistical
observations of intermolecular interactions which are derived from the experimental structures
(Tanaka and Scheraga 1976). The score is calculated as the sum of all pairwise contact scores
between the ligand and protein atoms. These energies are estimated by analyzing large datasets
like the Protein Data Bank (PDB). The pairwise scores are calculated according to the assumptions
that if an interaction has a lower energy, it will happen more often (Thomas and Dill 1996). So
frequent pairs get higher scores, and rare pairs get penalized. For protein–ligand studies, the
potentials are calculated by
w(r) = -kBT ln[g(r)]
g(r) = ρ (r)/ ρ *(r)
where kB is the Boltzmann constant, T is the absolute temperature of the system, ρ(r) is the number
density of the protein–ligand atom pair at distance r, and ρ *(r) is the pair density in a reference
state where the interatomic interactions are zero. Knowledge-based scoring is used in PMF,
ITScore, and DrugScore (Gohlke, Hendlich et al. 2000, Huang and Zou 2006, Huang, Grinter et
al. 2010).

2.4 Drug Repurposing
Drug discovery on average takes 10 to 15 years. Most of the tested molecules cannot progress to
the advanced stages (DiMasi, Hansen et al. 2003). Since 1995, only 10 percent of molecules in
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phase 1 studies actually made it to the clinical phase. That is why computational methods like
molecular docking are being adopted at every stage of the drug discovery pipeline and being used
to identify and eliminate targets. But even with the computer aid, drug discovery is a long process.

Figure 4. Illustration of the summary of the drug discovery.

One of the strategies to accelerate this process is drug repurposing. Drug repurposing (also known
as drug repositioning or reprofiling) is a technique for discovering new uses for existing drugs that
go beyond the original medical indication (Rudrapal, Khairnar et al. 2020). Since most of the
pipeline can be skipped, this approach ensures a fast time to market, an existing supply chain,
lower cost, and in some cases significant amounts of clinical data. Clinical data is especially
important as it would be very useful for expediting the pre-clinical and clinical test stages. Also,
since 45% of the drug lead failures are due to toxicity and safety issues, this approach would
increase the chances of success (Rudrapal, Khairnar et al. 2020).
There are many places where drug repurposing has been used and has been successful. For
example, Viagra, one of the most well-known drugs, was originally developed as an
antihypertensive drug, but Pfizer has repurposed and marketed this drug for erectile dysfunction
(Ghofrani, Osterloh et al. 2006). Another example is repurposing of the cancer drug Zidovudine
as an anti-HIV drug. Thalidomide is another famous example. It was developed as a sedative in
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the 1950s; but then repurposed as a leprosy and multiple myeloma therapies (Rahmat, Sklavenitis
Pistofidis et al. 2019).
However, drug repurposing has its own challenges too. Drugs are usually approved against certain
diseases at certain doses. When a drug is repurposed, it needs to go through clinical trials again,
and the appropriate doses need to be identified. Another issue is the delivery systems. A repurposed
molecule that is targeted to reach a certain tissue might require a different targeting mechanism
which would require some of the steps in the pipeline. Also, when a drug is being repurposed, its
interactions with other drugs that are used for the new indication need to be studied (Oprea,
Bauman et al. 2011). Regardless of these challenges a successful repurposing would fast track a
drug and save lives.
The best way to increase possible drug repurposing opportunities is to use computation methods.
All three computational methods would be applicable for this strategy. Virtual screening can be
done to identify approved drug molecules that interact with a specific target disease causing
protein. Or a specific drug molecule can be tested against all the crystal structures in the databases
to see if it interacts with any. Molecule libraries can be searched to find druggable, more effective
or free analogues of drug targets. Using networks, similarities between diseases and biological
processes can be identified, and drugs that work for one case can be tried on the other as well.
Molecular docking is used for virtually all these scenarios.

2.5 Molecular Docking and Drug Repurposing against SARS-CoV-2
Despite all the safety measures and vaccinations, at the time of writing SARS-CoV-2 was still
spreading quickly and causing a high number of deaths. Therefore, there is a huge worldwide effort
to find viable treatments against it. In the past year, a significant number of studies that used
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computational methods against SARS-CoV-2 were published. Due to the urgency of the matter,
molecular docking and drug repurposing was a common theme across these studies. Some of the
suggested repurposing targets have gone through clinical trials and are currently approved in
different countries.
Remdesivir, which is used for hepatitis C, is the only FDA-approved drug against SARS-CoV-2.
Remdesivir was approved by FDA in October, but before that, it was predicted as a promising
candidate by some in silico studies (Elfiky 2020, Naik, Munikumar et al. 2020). Later docking
studies that were carried out for this drug, also affirmed it as a promising candidate (Deshpande,
Tiwari et al. 2020). Finally, in a double-blind, randomized, placebo-controlled clinical study,
Remdesivir has been proven to shorten the healing process in adults who were hospitalized due to
Covid-19 (Beigel, Tomashek et al. 2020).
Ribavirin is another promising candidate against SARS-CoV-2. It is an antiviral medication which
is used to treat hepatitis C and respiratory syncytial virus (RSV) infection. Ribavirin was suggested
as a potential drug against SARS-CoV-2 in silico studies (Elfiky 2020, Peng, Shen et al. 2021).
Later, in another study, in silico results were strengthened with in vitro and it was observed that
Ribavirin showed anti-viral activity (Unal, Bitirim et al. 2020). In another clinical study, it was
observed that a treatment including Ribavirin shortened the duration of viral shedding (Hung, Lung
et al. 2020).
Arbidol, which is also known as Umifenovir, is another antiviral (anti-influenza) drug. It was
suggested that Arbidol may have efficacy against SARS-CoV-2 in an in silico study (Vankadari
2020). Then, in an in vitro study, it was shown to inhibit SARS-CoV-2 by partially blocking its
entry to the cells (Wang, Cao et al. 2020). In addition to this, in a clinical study conducted, it was
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shown to positively contribute to oxygen saturation, hospitalization duration, chest CTs. As a
result it was recommended for a study with a larger sample size (Nojomi, Yassin et al. 2020).
These 3 molecules were not the only suggested drug repurposing targets. Many other studies were
published, and different approaches were ventured. Different datasets such as, ZINC15,
SuperDRUG2, PubChem, ChEMBL, MTiOpenScreen, Thiol-reacting FDA-approved drugs,
medicinal plants, were docked against different targets such as PL protease (PDB: 6W9C), Main
protease (PDB: 6LU7), nsp15 protein (PDB: 6W01) and nsp-16 (PDB: 6WH4) (Arun, Sharanya
et al. 2020, da Silva Hage-Melim, Federico et al. 2020, Elmezayen, Al-Obaidi et al. 2020, Gyebi,
Ogunro et al. 2020, Lobo-Galo, Terrazas-López et al. 2020). Some of these studies did MD and
ADMED simulations as well. Main protease (Mpro), RdRp, spike protein and TMPRSS2 were
common docking targets. Saquinavir, Darunavir, lopinavir, Remdesivir, Indinavir, Galidesivir,
Saikosaponin, Raltegravir and Simeprevir were the most frequently suggested candidates. Most of
the studies did not have experimental validation data (Dotolo, Marabotti et al. 2021).
As can be seen from the examples above, some of the molecular docking results are actually
promising and can be verified by in vitro or clinic studies. Therefore, we investigated the efficacy
and the interactions of FDA-approved drugs against SARS-CoV-2 in this study.

2.6 Method
In this study, Autodock 4.2 and Autdock Vina were used as the main docking tools (Morris, Huey
et al. 2009, Trott and Olson 2010). Autodock 4.2 is an established and effective docking tool used
for protein-ligand docking. It uses a genetic algorithm called Lamarckian algorithm for
confirmation search and a semi-empirical force field function for scoring. It is being maintained
by Scripps Research and is succeeded by Autodock Vina. Autodock Vina is about two orders of
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magnitude faster than Autodock 4.2 and also has better accuracy at binding mode predictions. Vina
is multithreaded and can achieve parallelism on multi-core devices. It uses a stochastic search
method called Iterated Local Search global optimizer, which resembles a genetic algorithm with a
metropolis criterion. It also uses the Broyden-Fletcher-Goldfarb-Shanno (BFGS) method for
choosing the optimization direction. AutoDock Vina has a semi-empirical and semi-knowledge
based scoring function which is considered more of a machine learning algorithm (Trott and Olson
2010).
Since Experimental DRI-C molecules are novel drugs and are only synthesized in the lab, they are
not found in any of the databases. Therefore, the structures of the experimental DRI-C molecules
were manually drawn using the Avogadro software for molecular docking (Hanwell, Curtis et al.
2012). Methylene Blue and Erythrosine B structures were taken from the PubChem (Kim, Thiessen
et al. 2016). Three-dimensional crystal structures of SARS-CoV-2 spike receptor-binding domain
that is bound to ACE2 (PDB ID: 6M0J) at a resolution of 2.45 Å was downloaded from the
Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) (Lan, Ge
et al. 2020). Another PDB file was also created from 6M0J to isolate the spike protein.
Ligand Molecules were downloaded from the ZINC database, which is a collection of compounds
specifically designed for virtual screening. The downloaded molecules were in SDF format, which
is a text format that defines structure data through atoms, bonds, and coordinates. Then SDF files
were converted to PDB format, which is another text format that describes 3D molecules. This
conversion was done by OpenBabel, a toolkit designed to be the translator between different data
formats and disciplines (O'Boyle, Banck et al. 2011). PDB files were converted once again to
PDBQT format, which is very similar to PDB, but carries extra info about partial charges and atom
types. This conversion was done by MGTOOLS, which is a utility box that comes with Autodock
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4.2. At this point pdbqt files of the target protein (6M0J) and ligand were given to Autodock Vina
along with a configuration file which defines the area of interest. Once Vina is done, it prints out
the binding affinities for the top 9 poses. These were parsed using a BASH script and appended to
a CSV file. The best binding pose from Vina was rescored using Autodock 4.2. If the rescoring
values were similar PDBQT output files from Vina, they were overlayed on top of the original
structure using PyMol, which is a python-based 3D model visualization tool (Schrodinger 2015).
The resulting structure was then fed into PLIP, which identifies the non-covalent bonds between
ligands and structures (Salentin, Schreiber et al. 2015).
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Chapter 3 - in silico Study of The Experimentally Proved
SARS-Cov-2 Inhibitors and Use of Ligand Efficiency to
Validate the Molecular Docking Method
3.1 Introduction
In this study, we would like to filter and find promising drug molecules against SARS-CoV-2
using virtual screening/molecular docking tools. Before moving on to finding promising drug
molecules, we would like to verify our method. For this purpose, a number of experimental
molecules from other studies were used to evaluate how reliable the molecular docking method is
(Bojadzic, Alcazar et al. 2020, Bojadzic, Alcazar et al. 2020). These experimental molecules were
shown to inhibit SARS-CoV-2 in wet-lab experiments. Therefore, they were good reference points
for our study. FDA molecules with common features and interactions would be more likely to be
successful at inhibiting the virus. Also, since real world data for these molecules were available,
simulation results could be cross checked, and our method could be verified.
The experimental molecules that were used are novel drug molecules that were synthesized by the
researchers in their laboratories. Some of these molecules were used to target the CD40–CD154
Costimulatory Protein-Protein Interaction and acted as inhibitors (Bojadzic, Chen et al. 2018).
Therefore, researchers wanted to try their novel molecules against SARS-CoV-2. In their study,
they have tested DRI-C21041, DRI-C23041, DRI-C24041, DRI-C61041, DRI-C71041, DRIC91005, DRI-C2204745, Methylene Blue and Erythrosine B molecules against SARS-CoV-2, and
they showed that all of these molecules inhibited the interaction of the spike proteins of SARSCoV-2 with ACE2. Methylene Blue and Erythrosine B are actually dye molecules and are already
FDA approved. MeBlu is used for the treatment of methemoglobinemia, and has several other
therapeutic applications (Jack Clifton and Leikin 2003). EryB is a food colorant, and in another

28

study it was shown to be a potential protein–protein interaction inhibitor (Ganesan, Margolles-Clark
et al. 2011). The chemical structures of all the experimental molecules are shown in Figure 5.

Figure 5. Molecular structures of (A) DRI-C21041, (B) DRI-C23041, (C) DRI-C24041, (D) DRIC2204745, (E) DRI-C61041, (F) DRI-C71041, (G) DRI-C91005, (H) Methylene Blue, and (I)
Erythrosine B.

3.2 Method
Since Experimental DRI-C molecules are novel drugs and are only synthesized in the lab, they are
not found in any of the databases. Therefore, the structures of the experimental DRI-C molecules
were manually drawn using the Avogadro software for molecular docking (Hanwell, Curtis et al.
2012). Methylene Blue and Erythrosine B structures were taken from the PubChem database (Kim,
Thiessen et al. 2016). Three-dimensional crystal structure of SARS-CoV-2 spike receptor-binding
domain that is bound to ACE2 (PDB ID: 6M0J) at a resolution of 2.45 Å was downloaded from
the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) (Lan,
Ge et al. 2020). Another PDB file was also created from 6M0J to isolate the spike protein.
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DRI-C molecules, Methylene Blue and Erythrosine B were docked against both 6M0J and the
spike protein using Autodock Vina (Trott and Olson 2010). In order to account for the stochastic
behavior of docking, this exercise was repeated 100 times. Then, the molecules were rescored
using Autodock 4.2 to validate the method and results (Morris, Huey et al. 2009). The receptor
binding region with a sizable margin was used as the grid box. The grid box mapping parameters
for 6M0J along x, y and z directions respectively are as follows: (Å) x= 38 y= 78 z= 40 and Center
(Å) x= -36.139 center_y= 33.528 center_z= 3.444. And for the spike only structure parameters
are: (Å) x= 48 y= 60 z= 40 and Center (Å) x= -43.083 center_y= 38.667 center_z= 0.111. The best
binding pose of the molecule was overlayed to the target structure using PyMol to create a
combined new PDB file. Then PLIP was used to analyze and visualize the interactions of the
combined structure (Salentin, Schreiber et al. 2015, Schrodinger 2015).

3.3 Results and Discussion
The first step in validating our method was making sure that the binding affinity results were sane
and sensible. To verify this, structures were docked by Autodock Vina and rescored by Autodock
4.2. As can be seen in Figure 6, there is a clear trend between the Autodock Vina Binding Affinity
results and the Autodock 4.2 rescoring results. Based on this, we can say that the docking protocol
is validated.
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Figure 6. Autodock Vina Binding Affinity results and the Autodock 4.2 rescoring results of 6M0J
and spike protein structures.

After the method validation, the second step is to see whether there was a correlation between the
experimental results and the molecular docking results. Finding a significant correlation would
mean that when we apply our molecular docking method to the FDA approved drug molecules and
pick some targets, they would be likely to inhibit SARS-CoV-2 in the lab experiments as the
experimental molecules do.
Table 1 shows the binding affinity and rescoring results as well as the experimental IC50 values.
IC50 is a metric that indicates how much of a particular inhibitor is required in vitro experiments
to decrease a biochemical activity by half. (Aykul and Martinez-Hackert 2016).
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Table 1. IC50 Values, and Autodock Vina results of experimental molecules.
IC50 Values (ɱM)
DRI-C91005
EryB
DRI-C23041
DRI-C21041
MeBlu
DRI-C24041
DRI-C2204745
DRI-C61041
DRI-C71041

0.16
0.43
0.52
1.82
3.03
3.35
4.04
7.67
9.95

Whole Structure Vina Results
(kcal/mol)

-10.9
-8.1
-9.7
-10.3
-6.3
-9.5
-9.4
-10.4
-10

Spike Structure Vina Results
(kcal/mol)

-8.9
-6.4
-8.4
-8
-5.6
-7.6
-8.5
-7.6
-8

According to the IC50 values, DRI-C23041, DRI-C91005, and EryB can inhibit SARS-CoV-2 at
low molarities. However, there is no clear relationship between the docking/rescoring results and
experimental IC50 values of these molecules. Although DRI-C91005 ranks first in all categories,
EryB with the second lowest IC50 value would be expected to have the second-best docking
results. However, this is not the case, and since the IC50 values and binding affinity scores are
completely different concepts that measure different things, this is completely expected (Mikra,
Rossos et al. 2017). As can be seen in Figure 5, the molecules’ structures and their sizes are
significantly different, which affects the docking results and possible interactions.
Typically, larger compounds make more interactions with the target and therefore display higher
levels of binding energy. However, higher levels of binding energy may be misleading and do not
necessarily mean a more efficient binding. A smaller molecule with comparable binding energy
would probably make less interactions but bind more strongly. Since drug candidates often get
bulkier during the drug optimization stage, a smaller but more efficiently binding molecule is more
desirable. Ligand efficiency metric can be used to find such candidates during screening. Ligand
efficiency is calculated by dividing the binding energy of a compound by the number of its
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nonhydrogen atoms (Hopkins, Groom et al. 2004). This would mean that smaller molecules would
be picked over larger molecules exhibiting similar binding energies.
EryB is a significantly smaller molecule than DRI-C91005 and DRI-C23041. Therefore, it would
be expected to bind to the target molecule with less binding energy than the other two. However,
when the binding energy for all molecules were normalized with respect to their molecular
weights, comparison of the results would be more meaningful. Also, since binding efficiency can
be calculated both from IC50 and binding energy values, it can be used as a way of verifying the
relationship between the measured IC50 values in the lab and the docking results from simulations.
First ligand efficiencies for the experimental molecules were calculated using the equation 1,
where R is the gas constant (1.987×10−3 kcal⋅K−1⋅mol−1) and T is temperature (K). Then, the

predicted ligand efficiencies were calculated using equation 2, where the Autodock Vina binding
affinity results were used.
−𝐑𝐑𝐑𝐑 𝐥𝐥𝐥𝐥 𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈

𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍 𝐨𝐨𝐨𝐨 𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧 𝐚𝐚𝐚𝐚𝐚𝐚𝐚𝐚𝐚𝐚

𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁𝐁 𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟 𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞𝐞

The results were shown in Table 2.

𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍 𝐨𝐨𝐨𝐨 𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧𝐧 𝐚𝐚𝐚𝐚𝐚𝐚𝐚𝐚𝐚𝐚
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(1)

(2)

Table 2. Ligand Efficiency Results
Experimental (IC50)
Ligand Efficiencies
DRI-C91005
EryB
DRI-C23041
DRI-C21041
MeBlu
DRI-C24041
DRI-C2204745
DRI-C61041
DRI-C71041

0.1997
0.2837
0.2117
0.1934
0.3630
0.1844
0.1774
0.1723
0.1685

6M0J Autodock Vina
Results’ Ligand
Efficiencies

0.2319
0.2612
0.2365
0.2512
0.3
0.2317
0.2238
0.2536
0.2439

Only Spike Autodock
Vina Results’ Ligand
Efficiencies

0.1893
0.2064
0.2048
0.1951
0.2666
0.1853
0.2023
0.1853
0.1951

According to the paper, the experimental molecules were only bound to the spike protein
(Bojadzic, Alcazar et al. 2020). Figure 7 shows the comparison of actual and predicted ligand
efficiency results for the spike protein structure. There is a clear trend between the two sets of
results and the correlation is 0.90.

Figure 7. Ligand Efficiencies of Only Spike Structure and their correlation.
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However, when we are screening the FDA approved drugs, we decided to consider drugs that
would bind to the interface as well. Therefore, we repeated the procedure for the whole (PDB ID:
6M0J) structure as well. As Figure 8 shows, when the actual and predicted ligand efficiency results
for the whole structure are compared, a similar trend can be seen and the correlation is 0.86, which
is still quite high. This would mean that using the whole structure for docking would still give us
meaningful results and that the results that we get from docking closely follow the results from the
laboratory experiments.

Figure 8. Ligand Efficiencies of Whole Structure (6M0J) and their correlation.

As stated earlier, a high binding affinity may not always lead to an efficient binding or low IC50
value. To make better predictions, properties of the known to be inhibiting molecules can also be
used. One of the most important properties of the experimental drugs is where they bind to.
Molecules that make similar bonds with the experimental molecules would be more likely to
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inhibit SARS-CoV-2. Also finding hotspots that experimental molecules bind to can give us clues
about the inhibition potential of certain interactions.
With respect to the binding affinity results, DRI-C21041 is one of the top candidates (-10.3
kcal/mol). Its binding location to the 6M0J structure is shown in Figure 9(A), and its interactions
are shown in Figure 9(B). As seen in Figure 9(A), DRI-C21041 molecule binds to the interface of
ACE2 and spike protein of SARS-CoV-2. DRI-C21041 forms Hydrogen bonds with Asn33,
Thr92, Gln96 residues on ACE2, and with Arg403 on the spike protein. It only had hydrophobic
interactions with the ACE2 structure: Asn33, Glu37, Thr92, and Pro389.

Figure 9. (A) DRI-C21041 on 6M0J (B) Molecular Interactions between DRI-C21041 and 6M0J

DRI-C23041 molecule is slightly different from DRI-C21041. Their molecular sizes are the same;
but the SO3H group is bound to another carbon in DRI-C23041. As can be seen in Figure 10(A),
they bind to similar places on the 6M0J structure, and they share common interactions, which are
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visualized in Figure 10(B). DRI-C23041 makes hydrogen bonds with Glu3, Asn90 on the ACE2
and with Arg403 on the spike protein. It forms the exact same hydrophobic bonds that DRI-C21041
forms: Asn33, Glu37, Thr92, Pro389 DRI-C21041. DRI-C23041 also forms a salt bridge, a noncovalent interaction formed between two ionized molecules, with Lys26 on the ACE2 (Kurczab,
Śliwa et al. 2018).

Figure 10. (A) DRI-C23041 on 6M0J (B) Molecular Interactions between DRI-C23041 and 6M0J

DRI-C24041 has the same molecular weight and atoms as DRI-C21041 and DRI-C23041. Just
like DRI-C23041, it has SO3H in a different location. Despite the similar structure it exhibits a
lower affinity and a higher IC50 value. However, as Figure 11(A) shows, it makes about the same
interactions as the two other variants. The only minor difference is the pi-stacking it makes. pistacking is non-covalent interactions of aromatic molecules (Martinez and Iverson 2012).
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Figure 11. (A) DRI-C24041 on 6M0J (B) Molecular Interactions between DRI-C24041 and 6M0J

The next molecule is DRI-C61041. It has one of the higher binding affinities. It is similar to DRIC21041; but it has a Nitrogen atom bound to one of its aromatic rings. It exhibits most of the same
interactions as the previous molecules. It forms hydrogen bonds with Asn33, Gln96 on the ACE2
and with Arg403 on the spike protein. It forms hydrophobic bonds with Asn33, His34, Glu37,
Pro389, Tyr505. Its interaction with Tyr505 is interesting. Tyr505 is mentioned in the literature as
a hotspot (Veeramachaneni, Thunuguntla et al. 2020). Although due to its interactions and binding
score, DRI-C61041 seems promising, it actually has a higher IC50 value than the previous
molecules. It is one of the few molecules that stops the correlation from being 1.0 and implies that
the relationship between interactions and IC50 values is a complex one.
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Figure 12. (A) DRI-C61041 on 6M0J (B) Molecular Interactions between DRI-C61041 and 6M0J

DRI-C71041 is another molecule which has a high binding affinity. It has a similar structure as
DRI-C61041. However, one of its aromatic rings is five membered and has a Sulphur atom as the
fifth member. It exhibits similar hydrogen bonds as the other molecules. It makes hydrogen bonds
with Asn33, Gln96 on ACE2, and with Arg403 on the spike protein. It also makes two pi bonds,
one with His34 on ACE2 and one with Arg403 on the spike protein. Just like DRI-C61041, DRIC71041 seems promising but actually has one of the highest IC50 values.
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Figure 13. (A) DRI-C71041 on 6M0J (B) Molecular Interactions between DRI-C71041 and 6M0J

Compared to the previous molecules, DRI-C2204745 is a larger molecule. Therefore, it has more
interactions with the target structure. As Figure 14(A) shows, it binds to a different place than the
previous molecules. This molecule makes hydrogen bonds with Asp30, Asn33, Met323, Gln325,
Gln388 on ACE2, and with Gly504, Tyr505 on the spike protein. It also makes hydrophobic bonds
with Asn33, Thr324, Ala387, Pro389 on ACE2, and with Val503, Tyr505 on the spike protein. It
has some salt bridge interactions as well. It forms salt bridges with His34 and Arg403. Although
it shares some interactions with the previous molecules, it also exhibits unique interactions with
the RBD as well. Also, it has a decent binding affinity score, -9.4 kcal/mol.
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Figure 14. (A) DRI- C2204745 on 6M0J (B) Molecular Interactions between DRI- C2204745 and
6M0J

DRI-C91005 is the top molecule in the group. It ranks highest both in IC50 and binding affinity
results. As Figure 15(A) shows, this molecule binds to a different place than the other molecules
and does not have any common interactions. However, according to the literature, its binding
location is still within the RBD. The reason for a different binding location might be DRI-C91005
being a larger molecule than the others. As molecules get larger their binding areas grow as well,
and this leads to higher affinity results (Kuntz, Chen et al. 1999). DRI-C91005 makes hydrogen
bonds with Asn49, Asn58, Gln76 on ACE2, and with Gly485, Asn487 on the spike protein. Gly485
is an important interaction. According to literature Gly485 is another hotspot on the spike protein
(Shang, Ye et al. 2020). DRI-C91005 also makes hydrophobic bonds with Lys31, Leu39, Gln42,
Ala46, Asn61, Lys68.
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Figure 15. (A) DRI-C91005 on 6M0J (B) Molecular Interactions between DRI-C91005 and 6M0J

Unlike the DRI-C molecules, EryB is a dye molecule. As Figure 5 shows, it is a significantly
smaller molecule than the others. This explains why it has lower binding affinity than the others
(Kuntz, Chen et al. 1999). Although it has a lower binding affinity, according to the IC50 values,
it can inhibit SARS-CoV-2 with one of the lowest molarities within the group. Just like the others
it binds to the RBD. It makes hydrogen bonds with Arg393 on ACE2, and with Arg408, Tyr505
on the spike protein. All three of these interactions are mentioned as hotspots in the literature (Ali
and Vijayan 2020, Shang, Ye et al. 2020, Veeramachaneni, Thunuguntla et al. 2020). It also makes
hydrophobic bonds with Thr324, Phe356, Met383, Ala386, Tyr505; all of which are in the RBD.
Another interesting property of Ery B is it was suggested as a potential PPI in a study (Bojadzic,
Chen et al. 2018). Due to all of these properties it makes a good reference point for our screening.
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Figure 16. (A) EryB on 6M0J (B) Molecular Interactions between EryB and 6M0J

Our last molecule is MeBlu, an FDA approved dye. Although it is a dye molecule it is also used
to treat methemoglobinemia, a condition where blood can’t carry oxygen to the body (Jack Clifton
and Leikin 2003). MeBlu was also tested in a clinical study against SARS-CoV-2. It was
administered as a part of a cocktail and showed promising results. (Alamdari, Moghaddam et al.
2020). As Figure 17(A) shows it is the only molecule in the group that only binds to ACE2. It has
a smaller structure than the others and does not make any hydrogen bonds. However, it makes
hydrophobic bonds with Phe40, Leu73, Phe390, Leu391. Due to its small size and lack of hydrogen
bonds, it has a lower binding affinity than the others (Kuntz, Chen et al. 1999). Since it was
suggested as a potential SARS-CoV-2 drug in other studies as well, it is another important
reference point for our screening (Ghahestani, Shahab et al. 2020, Scigliano and Scigliano 2021).
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Figure 17. (A) MeBlu on 6M0J (B) Molecular Interactions between MeBlu and 6M0J

All of the experimental molecules’ interactions are listed in Table 3 for better visualization.
Interactions with ACE2 and S protein were annotated with (A) and (E) suffix, respectively.
Table 3. Molecular Structures and Interactions of Experimental Molecules.
Molecule

DRIC21041

Binding Affinity
(kcal/mol)

Hydrogen / pi Interactions / Salt Bridge

-10.3

Asn33(A), His34(A), Thr92(A), Gln96(A),
Arg403(E)

DRIC23041

-9.7

His34(A), Glu37(A), Asn90(A),
Arg403(E)

DRIC24041

-9.5

Glu37(A), Asn90(A), Thr92(A),
Arg403(E), pi: Arg403(E)

DRIC61041

-10.4

Asn33(A), Gln96(A), Arg403(E)

DRIC71041

-10

DRIC91005

-10.9

Asn33(A), Thr92(A), Gln96(A),
Arg403(E), pi: His34(A), Arg403(E)
Asn49(A), Asn58(A), Gln76(A),
Gly485(E), Asn487(E)

44

Hydrophobic Interactions

Asn33(A), His34(A),
Glu37(A), Thr92(A),
Pro389(A)
Asn33(A), Glu37(A),
Thr92(A), Pro389(A),
Tyr495(E)
Asn33(A), Glu37(A),
Thr92(A), Pro389(A),
Tyr495(E)
Asn33(A), His34(A),
Glu37(A), Pro389(A),
Tyr505(E)
Lys26(A), Leu29(A),
Glu37(A), Val93(A),
Pro389(A), Tyr505(E)
Lys31(A), Leu39(A),
Gln42(A), Ala46(A),
Lys68(A)

DRIC220474
5

-9.4

MeBlu

-6.3

Asp30(A), Asn33(A), Met323(A),
Gln325(A), Gln388(A), Gly504(E),
Tyr505(E), Salt Bridge: His34(A),
Arg403(E)
-

Ery B

-8.1

Arg393(A), Arg408(E), Tyr505(E)

Asn33(A), Thr324(A),
Ala387(A), Pro389(A),
Val503(E), Tyr505(E)
Phe40(A), Leu73(A),
Phe390(A), Leu391(A)
Thr324(A), Phe356(A),
Met383(A), Ala386(A),
Tyr505(E)

All of the experimental drugs inhibit SARS-CoV-2 in a laboratory setting, albeit with different
IC50 values. As Table 3 shows, with the exception of MeBlu, all of them have good binding
affinity scores, which were verified by two different scoring tools. The validity of the docking
method was also tested by calculating the ligand efficiency both from simulation results and the
real world IC50 data. Since the results were consistent, we have a high degree of confidence that
simulation results for FDA approved drugs would also be fairly reliable.

3.4 Conclusion
Simulations are approximations to real life. Their results are not always accurate or even reliable.
Since this study relies on simulations heavily, first our method had to be verified and its predictions
had to be compared against the real-life experiment results. These seven novel experimental
molecules and two FDA-approved dye molecules that were shown to inhibit SARS-CoV-2 in a
laboratory setting were analyzed. These molecules were docked against the spike protein and
ACE2 complex. The resulting poses were scored using two different functions and showed similar
trends, which verified our scoring function. IC50 values of these molecules from the wet-lab
experiments were available and binding affinity scores had to be compared against them. However,
IC50 and binding affinity do not measure the same things and cannot be compared against each
other directly. Therefore, a metric, which can be calculated from both values was used as the
common ground. This metric is called ligand efficiency, and it measures binding energy per atom.
When it was calculated from real-life IC50 values and binding affinity score, resulting datasets
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showed similar trends and a correlation of 0.86. This showed that there was a strong relationship
between the lab results and simulation results. Therefore, we have a high degree of confidence that
simulation results for FDA-approved drugs would also be fairly reliable.
However, docking results could be supported by extra predictors. Although the experimental
molecules have some unique interactions, they also have a decent amount of common interactions,
which is significant. They also bind to some residues that are mentioned in the literature as
hotspots. Any FDA approved drug having a decent binding affinity and binding to the residues
that the experimental drugs bind would likely have similar properties as the experimental drugs
and would be a potential target for repurposing.
Of the nine experimental molecules, 8 of them exhibited high binding affinities and made
interactions with both ACE2 and spike protein. The remaining one, MeBlu, only interacted with
ACE2 and had a lower binding affinity. This suggests that drugs that do not interact with the spike
protein at all, could still be effective against SARS-CoV-2.
Amongst the experimental molecules, hydrophobic bonds with Pro389, Glu37, Asn33, Thr92 and
Tyr505, as well as hydrogen bonds with Asn33, His34, Thr92, Gln96, Tyr505 and Arg403 were
common. Of these residues Glu37, His34 and Tyr505 were mentioned as hotspots in the literature.
However, the molecule with the best performance, DRI-C91005, did not have any common
interactions with the rest of the molecules. On the other hand, it interacted with Asn487, which is
suggested as a hotspot on the spike protein. Since all of these molecules inhibit SARS-CoV-2, any
FDA approved drug that shows similarities will be considered as promising.
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Chapter 4 - Identifying Drug Repurposing Candidates for
SARS-CoV-2 from FDA-Approved Drugs Using Molecular
Docking Tools and Interaction Analysis
4.1 Introduction
Every drug prescribed in the United States has to be tested for safety and efficacy first. The
government body that performs these tests and regulates the drug market is called The United
States Food and Drug Administration, FDA. FDA tests are stringent and time-consuming. Of the
5000 compounds that reach the preclinical study stage, only one gets approved. Of the 10
compounds that reach the clinical studies, only one makes it to the market. The whole process
takes 10 to 15 years. Therefore, a de novo drug getting approval in a short amount of time is
unlikely. This makes the repurposing of previously approved drugs the most viable strategy for
quick results.
The high death toll and the time sensitive nature of the pandemic has led to a lot of in silico and in
vivo repurposing studies. Some of these were covered in the second chapter. In these studies,
different stages of the virus activity and different parts of the virus were targeted. While some
studies concentrated on the main protease, others focused on the spike protein and RBD (AboZeid, Ismail et al. 2020, Absalan, Doroud et al. 2020, De Vita, Chini et al. 2020).
The goal of this study is to find FDA-approved drug candidates that could bind to RBD and inhibit
the virus activity. Molecular docking method, which was verified on the experimental drugs in
chapter 3, will be used to analyze how FDA approved molecules interact with the spike protein.
Results from experimental drugs and previous repurposing studies will be used as reference points
to identify the best candidates.
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4.2 Method
During the virtual screening 1750 FDA approved molecules from the ZINC database were used.
Each molecule was docked against the 6M0J structure using Autodock Vina. In order to decrease
the bias, docking boxes from other studies were expanded. However, if the box is chosen too large,
then docking takes a very long time and the probability of missing the binding domain increases.
On the other hand, if a very small box is chosen, then the molecules are forced to bind at a setting
which might not be the optimal energy solution. Therefore, a midsize box that contains the RBD
was used. It is shown in Figure 18.

Figure 18. Grid box region which is used for molecular docking.

Molecules were ranked according to their binding affinities and the top 50 molecules were picked
for further analysis. These 50 drugs and their affinities can be seen in Table 4.
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Table 4. Top 50 FDA approved drugs and their binding affinities.
Ligand
Voxilaprevir
Eltrombopag

Binding
Affinity
(kcal/mol)
-10.9
-10.5

Sirolimus

Ligand

Ligand

Altabax
Erismodegib

Binding
Affinity
(kcal/mol)
-9.6
-9.5

Orap
Itc

Binding
Affinity
(kcal/mol)
-9
-9

-10.4

Retapamulin

-9.5

Atacand

-9

Venetoclax

-10.4

Montelukast

-9.5

Everolimus

-9

Lumacaftor

-10.1

-9.5

Axitinib

-8.9

Avapro

-10.1

Dihydroergotamin
e
Imatinib

-9.5

Glimepiride

-8.8

Paritaprevir

-10.1

Glecaprevir

-9.5

Suvorexant

-8.8

Emend

-10

Abemaciclib

-9.4

Eribulin

-8.8

Rolapitant

-10

Irinotecan

-9.4

Stendra

-8.7

Cabazitaxel

-10

Ibrutinib

-9.4

Lomitapide

-8.7

Rifabutin

-9.9

Ledipasvir

-9.4

Stivarga

-8.7

Nilotinib

-9.8

Elbasvir

-9.3

Vorapaxar

-8.7

Simeprevir

-9.8

Midostaurin

-9.2

Flibanserin

-8.6

Saquinavir

-9.8

Conivaptan

-9.2

Ergotamine

-8.6

Avodart

-9.8

Indacaterol

-9.1

Lurasidone

-9.8

Tpv

-9

Naldemedine

-9.7

Amaryl

-9

Olaparib

-9.6

Telmisartan

-9

As mentioned in chapter 2, in order to make computations manageable, docking tools use
approximations and stochastic methods. Therefore, their results should be verified. Autodock 4.2
was used to rescore the top 50 candidates. Figure 19 shows the comparison of Autodock Vina and
Autodock 4.2 scores. Results follow similar trends and despite a couple of outliers, the root mean
square distance between the two sets is 0.85.
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Figure 19. Comparison of Autodock Vina and Autodock 4.2 Rescoring Results.

To make sure that our remaining 50 molecules were not random, an extra step of verification was
done. If there were any drugs that are similar to the experimental drugs, it would be likely that at
least some of them would be in the remaining 50. However, measuring the similarities of 1750
molecules is not an easy task. To be able to do this programmatically these molecules need to be
quantized and a measurement metric needs to be set.
The former can be done using a technique called molecular fingerprinting. There are two major
fingerprinting strategies, structure based, and hash based. In the former, bits usually show the
presence of certain substructures and their order. In the later, all linear substructures in the
molecule are enumerated and passed through a hash function (Haider 2010).
Once the molecules are quantized into vectors of bits, the next step is comparing them. The most
commonly used metric for this task is Tanimoto Similarity coefficient (Bajusz, Rácz et al. 2015).
Tanimoto coefficient is calculated by dividing the number of common bits between the two vectors
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to the number of bits in their union. A value of 0 would mean that there is no similarity, and 1
would mean that the two vectors are identical (Tanimoto 1958). Since different fingerprinting
algorithms use different bit schemes, a universal similarity threshold is not possible to be set.
However, when using the Daylight fingerprinting algorithm a Tanimoto Similarity coefficient
larger than 0.85 means that two molecules are similar (Cereto-Massagué, Ojeda et al. 2015).
There are many different fingerprinting algorithms that use different approaches. In order to
decrease the variance, three different algorithms, Daylight, Morgan, and Torsion, were used.
Experiments were done on Python using the RDKIT library (Landrum 2016). Each of the 9
experimental drugs were compared against each of the 1750 FDA-approved drugs using the three
different fingerprinting algorithms and Tanimoto Similarity. For each experiment, 10 FDA
approved drugs with the highest similarity scores were picked. As a result, 3 collections (one for
each fingerprinting algorithm) of 10 results were gathered for each of the 9 experimental
molecules; in other words, a total of 270 data points were collected. In order to remove the outliers,
only the most commonly recurring molecules were considered. From these results variants of the
same molecules were dropped and the top 10 most occurring molecules were picked. Table 5
shows the results.
Table 5. Top 10 most occurring similar molecules.
Molecule

Binding Affinity
(kcal/mol)

Number of Occurrence in
Similarity Experiments

Dihydroergotamine

-9.5

26

Ergotamine

-8.3

22

Saquinavir

-9.7

18

Elbasvir

-9.3

12

Bromocriptine

-8.0

12

Velpatasvir

-8.1

10

Paritaprevir

-10.1

9
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Exist in TOP 50

Naldemedine

-9.7

9

Rifabutin

-9

9

Ledipasvir

-9.1

9

From the top 10 most occurring molecules, 8 of them were in the remaining 50, which means that
our filter worked as expected. However, the Tanimoto similarity scores for the Daylight fingerprint
experiments ranged between 0.7-0.73, which means that none of the FDA approved drugs passed
the 0.85 threshold.
Once there were only 50 molecules left, the next step was studying the binding locations and
interactions. However due to the stochastic nature of the docking tools relying on a single set of
results would not be enough. Therefore, docking experiments were repeated 100 times to decrease
the variance in the results. The BASH scripts which were used for our method were included in
Appendix A. Results from the iterations were overlaid using PyMol, and binding affinity
distributions were plotted using Matplotlib library of Python (Hunter 2007).
Some of the molecules showed significant variance across the iterations. Their binding affinities,
interactions, and even binding locations changed significantly. Some did not even consistently
bind to RBD. These molecules were filtered out. Figure 20 shows one of the eliminated molecules,
Vorapaxar. It binds to multiple different places on the structure and exhibits binding affinities
ranging from -8.4 to -9.7. Since it cannot consistently bind to the binding domain, it would be
unlikely to inhibit the spike protein activity.
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Figure 20. (A) 6M0J Structure docked with Vorapaxar (B) Binding affinity distribution of 100
iterations

The remaining molecules were evaluated with respect to their interactions. Each molecule’s most
frequently seen binding affinity was determined and 5 poses with that affinity were randomly
picked. These samples were analyzed with the PLIP software, and their interactions were recorded.
Molecules which show incoherent interactions were filtered out.
According to the literature Glu35, Tyr83, Asp38, Lys31, Glu37, His 34, Lys353, and Arg393 are
hotspots on ACE2. On the other hand, Gln493, Gln 498, Asn487, Tyr505, and Lys417 are hotspots
on the spike protein (Ali and Vijayan 2020, Veeramachaneni, Thunuguntla et al. 2020). Drug
molecules that interact with these residues were favored over ones that don’t. Another metric used
was similarity to the experimental drugs. Some of the interactions were common amongst the
experimental molecules. Asn33(5/9), His34(5/9), Arg403(5/9), Glu37(5/9), Tyr505(4/9),
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Thr92(3/9), and Gln96(3/9) interactions were frequently seen between experimental molecules and
the RBD. Drug molecules that made these interactions were preferred over the others.

4.3 Results and Discussion
After rounds of eliminations 10 molecules were left. They are shown in Table 6.
Table 6. Molecular Structures and Interactions of top 10 FDA approved drug molecules.
Molecule

Structure

Binding
Affinity
kcal/mol

Hydrogen / pi / Halogen
Interactions

Voxilaprevir

-10.9

Sirolimus

-10.4

Asn33(A), His34(A),
Asp38(A), Gln96(A),
Lys353(A), Arg403(E), pi:
His34(A), Arg403(E)
Thr27(A), His34(A),
Lys417(E)

Lys26(A), Leu29(A),
Asn33(A), Glu37(A),
Phe390(A),
Lys417(E), Tyr453(E)
Asn33(A), Pro389(A),
Asp405(E)

Paritaprevir

-10.1

Ser19(A), Thr27(A),
Lys417(E), Tyr421(E),
Tyr473(E), pi: Lys26(A)

Glu23(A), Lys26(A),
Leu29(A), Val93(A),
Tyr473(E)

Cabazitaxel

-10

Asn33(A), Gln409(E),
Lys417(E)

Lys26(A), Asn33(A),
Val93(A), Lys417(E)

Simeprevir

-9.8

Asp30(A), Asn33(A),
Arg393(A), Lys417(E),
Tyr505(E), pi: His34(A)

Lys26(A), Lys417(E)

Saquinavir

-9.7

Lys26(A), His34(A),
Glu37(A), Val93(A),
Pro389(A), Tyr495(E)

Glecaprevir

-9.5

Irinotecan

-9.4

Indacaterol

-9.1

Lys26(A), Asp30(A),
His34(A), Arg403(E),
Glu406(E), Lys417(E), pi:
His34(A), Salt Bridge:
Asp30(A)
Arg393(A), Arg403(E),
Arg408(E), Gln409(E),
Lys417(E), Tyr505(E),
Halogen: Asn33(A)
Thr27(A), Asn33(A),
Arg393(A), Lys417(E),
Tyr473(E)
Ser47(A), Asp350(A), pi:
Trp349(A)
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Hydrophobic
Interactions

Leu29(A), Asp30(A),
Ala387(A), Pro389(A),
Glu406(E)
Glu23(A), Lys26(A)
Phe40(A), Asp350(A),
Phe390(A), Arg393(A)

Ergotamine

-8.6

Asp30(A), Arg403(E),
Tyr505(E)

Leu29(A), Asn33(A),
Val93(A), Pro389(A)

Voxilaprevir is an anti-viral drug used to treat Hepatitis C. It reversibly binds to and inhibits the
nonstructural (NS) protein 3/4A protease (Heo and Deeks 2018). When used with other Hepatitis
C drugs, daclatasvir and sofosbuvir, it has been shown to inhibit SARS-CoV-2 in multiple studies
(Jockusch, Tao et al. 2020, Sacramento, Fintelman-Rodrigues et al. 2020). In our study, the
Voxilaprevir molecule has the highest binding affinity (-10.9 kcal/mol) amongst the selected
molecules. As the Figure 21(A) demonstrates, Voxilaprevir binds directly to the RBD region of
the whole structure and shows very little variance in binding location and affinity during the
iterations (Figure 21(B)). As can be seen in Figure 21(C), Voxilaprevir forms 6 Hydrogen, 2 pi,
and 7 Hydrophobic interactions with the interface. It binds to Asn33, His34, and Arg403 which
are common with DRI-C21041, DRI-C23041, DRI-C61041, DRI-C71041, DRI-C2204745.
Its Arg403 and Lys353 interactions are worth a mention. Arg403 interaction was seen in other
studies where proposed molecules were claimed to inhibit SARS-CoV-2 (Gurung, Ali et al. 2021).
In the same manner, Lys353 interaction was seen in a study where Dalbavancin molecule was
claimed to be effective against SARS-CoV-2 in animal trials (Wang, Yang et al. 2021). In another
study Lys353 was shown to be bonding with the spike protein, despite the inhibition of the ACE2
(Gangadevi, Badavath et al. 2021). Since Voxilaprevir makes both of the interactions, it is a
promising candidate. Also, since it is a protease inhibitor, it can be effective against the SARSCoV-2 replication.
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Figure 21. (A) 6M0J Structure docked with Voxilaprevir (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Voxilaprevir.

The next drug in our list is a mTOR inhibitor, which is used as an immunosuppressant agent.
mTOR inhibitors are used to reduce the sensitivity of T and B immune cells to interleukin-2 (IL2), which inhibits these cell’s activation (Nguyen, Vautier et al. 2019). There is a study that claims
that mTor inhibitors can be used against SARS-CoV-2 (Husain and Byrareddy 2020). In our study,
Sirolimus exhibits a low binding affinity (-10.4 kcal/mol) and stable results throughout the 100
iterations (Figure 22(B)). It forms 3 hydrogen bonds, one of which is with the His34 residue, a
common interaction with the experimental molecules and also a hotspot.
It also makes a hydrogen bond with Lys417, which is a hotspot as well. Lys417 was studied in an
in vitro study as well and was deemed as an important interaction (Gangadevi, Badavath et al.
2021). Although this drug does not make too many hydrogen bonds, distances for the ones it
makes are below 3 Å, which suggests a strong binding.
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Sirolimus also makes a hydrophobic bond with Asp405, which is not a common interaction among
the experimental or FDA-approved drugs. However in some studies it was suggested to be a
promising interaction (Mohammadi, Heidarizadeh et al. 2020, Tariq, Mateen et al. 2020).
Sirolimus makes its other hydrophobic bonds with Asn33 and Pro389 of ACE2, which are both
common hydrophobic bonds that the experimental molecules make.

Figure 22. (A) 6M0J Structure docked with Sirolimus (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Sirolimus.

Paritaprevir is an antiviral that is used to treat Hepatitis C and it targets the NS3-4A serine protease.
It shows very little variance in the iterations and has a binding affinity of -10.1 kcal/mol.
Paritaprevir makes 4 hydrogen bonds. One of its hydrogen bonds is with Lys417, which is a
hotspot. It also makes a hydrogen bond with Tyr473, which is similar to Glecaprevir. Tyr473 is
considered to have modestly important residue. Its other hydrogen bond interactions, Ser19 and
Thr27 are not seen in the experimental molecules. However, they are both located in the beginning
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of the helix region of ACE2, which is considered as one of the most important regions (Guo, Chen
et al. 2020). Paritaprevir also makes a pi stacking interaction with Lys26 and 5 hydrophobic bonds.
Although these residues are not seen in experimental molecules, they are seen in other Hepatitis C
drugs in our list. It is also suggested as a RNA polymerase inhibitor for SARS-CoV-2, which
makes it more promising (Gurung, Ali et al. 2021). And it is suggested as a repurposing target for
SARS-CoV-2 in another study as well (Mevada, Dudhagara et al.).

Figure 23. (A) 6M0J Structure docked with Paritaprevir (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Paritaprevir.

One of the molecules with the highest binding affinity scores in the list is Cabazitaxel. It was
fairly consistent during the iterations and is used to treat prostate cancer. It makes 3 hydrogen and
4 hydrophobic bonds. Its hydrogen and hydrophobic bonds with Asn33 are common with the DRIC experimental molecules. Its other interaction is with Lys417, which is a hotspot. It makes a
hydrogen and a hydrophobic bond with this residue. And its last hydrogen bond is with Gln409,
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which was seen in other studies but is not the most promising interaction. Although Cabazitaxel is
a strong candidate due to its high affinity and important interactions, it also has a possible
downside. Cabazitaxel is a chemotherapeutic agent and it can cause Neutropenia, a low count of
a certain white blood cell type (Assi, Ibrahim et al. 2020). Due to this risk Cabazitaxel needs to be
carefully studied.

Figure 24. (A) 6M0J Structure docked with Cabazitaxel (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Cabazitaxel.

Simeprevir is another hepatitis C drug that inhibits the nonstructural (NS) protein 3/4A protease
(Ouwerkerk-Mahadevan, Snoeys et al. 2016). Simeprevir has already been suggested to be
effective against other viruses (Li, Yao et al. 2019). It also has been proposed to be effective against
SARS-CoV-2 in another in silico, molecular dynamics study (Trezza, Iovinelli et al. 2020). In our
study, Simeprevir has exhibited a high binding affinity (-9.8 kcal/mol) and results were
homogeneous (Figure 25B). As can be seen in Figure 25C, Simeprevir forms 5 Hydrogen, 1 pi,
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and 2 Hydrophobic interactions with the interface. It makes a hydrogen bond and hydrophobic
bond with Lys417, which is a hotspot (Gangadevi, Badavath et al. 2021). It shows similarities to
DRI-C23041, DRI-C61041, DRI-C71041, DRI-C2204745 as well: it makes hydrogen bonds with
Asn33, Tyr505 and a pi bond with His34, another hotspot.
Simeprevir has also 2 common interactions with Ery B: Arg393 and Tyr505, both of which are
hotspots. They are commonly seen in silico studies (Benítez-Cardoza and Vique-Sánchez 2020,
Sethi, Sanam et al. 2020). In an in vivo study Arg393 was also suggested to be a key residue for
inhibition (Wang, Yang et al. 2021). Like Voxilaprevir, Simeprevir is a protease inhibitor and can
also be effective against virus replication as well.

Figure 25. (A) 6M0J Structure docked with Simeprevir (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Simeprevir.

Saquinavir is an antiretroviral drug used to treat HIV. It is a protease inhibitor that is used to reduce
the HIV virus load in the body, which slows down the disease and treats the symptoms. It has been
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suggested as a SARS-CoV-2 remedy in multiple studies (Bello, Martínez-Muñoz et al. 2020,
Montenegro, Al-Abed et al. 2020). Saquinavir is one the drugs with the lowest binding affinities
(-9.7 kcal/mol) and the most uniform interactions in our study. It forms 6 Hydrogen, 6
Hydrophobic, and 1 pi bonds. Saquinavir interacts with His34 on ACE2 and with Arg403 in Sprotein, which are common in DRI-C molecules. It also makes hydrogen bonds with Asp30 and
Lys417. Additionally, it makes a salt bond with Asp30 as well. Lys417 is a hotspot on the RBD
and in the absence of an inhibitor it usually interacts with Asp30 on ACE2 (Ali and Vijayan 2020).
Therefore, its bonds with Asp30 and Lys417 are important.
Saquinavir also makes a hydrogen bond with Glu406 on the spike protein. The distance for this
bond is below 3 Å. In a study published in 2015, a compound found in soybeans, Nicotianamine,
was shown to inhibit ACE2. This compound was tested against SARS-CoV-2 in silico and was
found to bind to Glu406 (Takahashi, Yoshiya et al. 2015, Chen and Du 2020). Saquinavir’s other
interaction with the spike protein is the hydrogen bond it makes with Gln409. This interaction was
not seen in experimental molecules. However, according to the literature, it is one of the strong
bonds that Naltrexone makes in molecular dynamics studies. According to in vitro studies,
Naltrexone is a promising molecule for SARS-CoV-2 inhibition (Choubey, Dehury et al. 2020).
Additionally, Saquinavir makes a hydrophobic bond with Tyr495. Amongst the experimental
molecules, this interaction was only seen in DRI-C23041. However, it was mentioned as a
promising interaction in literature (Sethi, Sanam et al. 2020, Farouk, Baig et al. 2021).
Saquinavir is one of the molecules with the most number of interactions in our list. It interacts with
multiple hotspots and residues covered in the literature. It is also a protease inhibitor as well. So,
like other drugs in our list, it has potential to disrupt SARS-CoV-2 at different stages.
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Figure 26. (A) 6M0J Structure docked with Saquinavir (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Saquinavir.

Glecaprevir is the third hepatitis C antiviral drug in our list. Like Voxilaprevir and Simeprevir, it
inhibits the nonstructural (NS) protein 3/4A protease, which prevents the cleavage of the HCV
polyprotein (Ng, Tripathi et al. 2018). In our study, Glecaprevir has exhibited a high binding
affinity (-9.5 kcal/mol), and consistently made the same bonds throughout the iteration (Figure
27B).
Just like Saquinavir, it has a high number of interactions.

As can be seen in Figure 27C,

Glecaprevir forms 6 Hydrogen, 1 Halogen, and 5 Hydrophobic interactions within the interface.
Its hydrogen bonds with Arg403 and Tyr505 are common with the DRI-C molecules. It also makes
a halogen bond with Asn33, which is a residue, experimental molecules frequently interact with.
Its interactions with Arg393, Arg408, and Tyr505 are exactly the same as Ery B. Furthermore,
Glecaprevir exhibits the Lys417 interaction which is common with Simeprevir and is a hotspot.
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More importantly, it was suggested as an inhibitor for the SARS-CoV-2 main protease as well
(Shamsi, Mohammad et al. 2020).
With the exception of Gln409, all of Glecaprevir’s interactions are either with hotspots or
frequently seen amongst the experimental molecules or covered in the literature. Actually Gln409
was also seen in some in silico studies (Tariq, Mateen et al. 2020, Jena, Kanungo et al. 2021).
However, in our study, its bond distance was 3.96 Å. Although distances smaller than 4 Å are
considered as hydrogen bonds in literature, this bond is unlikely to be as strong as the
others. Despite this both bonds with ACE2 and bonds with the spike protein are close to each
other. This suggests a strong inhibition potential.

Figure 27. (A) 6M0J Structure docked with Glecaprevir (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Glecaprevir.

Another molecule that has a low binding affinity (-9.4 kcal/mol) and exhibits uniform interactions
throughout the 100 iterations is Irinotecan (Figure 28(B)). This drug inhibits topoisomerase, an
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enzyme which controls the structure of DNA and plays a role in replication. It is used to treat
various kinds of cancer. Irinotecan forms 5 Hydrogen bonds: with Thr27, Asn33, and Arg393 from
ACE2, and with Lys417 and Tyr473 from the RBD. The Asn33 residue is common with most of
the DRI-C molecules and Arg393 is common with EryB. Also, Lys417 is an important hotspot. Its
other hydrogen bond with the spike protein is noteworthy as well. Tyr473 is mentioned in multiple
studies as forming modestly strong bonds with Asp30 of ACE2 (Alexander, Schoeder et al. 2020,
Ali and Vijayan 2020). Although it is not a hotspot, interacting with it would increase the chances
of inhibition. Besides its interactions and binding affinity, there is another factor which makes
Irinotecan a candidate. In one in vivo study, Topoisomerase 1 inhibition therapy was shown to be
effective against inflammation caused by SARS-CoV-2 (Ho, Mok et al. 2020).

Figure 28. (A) 6M0J Structure docked with Irinotecan (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Irinotecan.
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Our next molecule is Indacaterol, which is used to treat bronchitis (Cazzola, Calzetta et al. 2014).
Unlike our other molecules, it only binds to ACE2. Although this looks like an issue at the first
glance, there are studies suggesting that it is possible to inhibit SARS-CoV-2 by only binding to
ACE2. Actually, one of the experimental molecules does exactly that. MeBlu only binds to ACE2
and was shown to inhibit SARS-CoV-2 in vitro experiments. Just like MeBlu, Indacaterol is a
small molecule, and it exhibits a decent binding affinity (-9.1 kcal/mol). However, its interactions
are very different from the other molecules. It makes a double hydrogen bond with Ser47, a
hydrogen bond with Asp350, a triple hydrophobic bond with Phe40, a double hydrophobic bond
with Phe390, and hydrophobic bonds with Asp350 and arg393. It also makes a pi stacking
interaction with Trp349. All these interactions happen inside of the ACE2 binding domain. These
exact iterations were seen in another in silico study, where Catechin, a plant metabolite, was tested
against SARS-CoV-2 (Jena, Kanungo et al. 2021). Since Catechin was shown to be effective
SARS-CoV-2 in vivo experiments, Indacaterol is promising as well.
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Figure 29. (A) 6M0J Structure docked with Indacaterol (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Indacaterol.

The last drug in our list with a lower end binding affinity score is Ergotamine. It is used to treat
migraines and has a similar structure to EryB. It is a smaller molecule, and it only makes hydrogen
bonds with the RBD of spike protein. Ergotamine makes hydrogen bonds with Arg403 and Tyr505,
which are both common interactions amongst the experimental molecules. The latter, Tyr505, is
also a hotspot. Ergotamine also makes a hydrogen bond with Asp30. In normal conditions Asp30
interacts with Lys417 of the spike protein, another hotspot. So Asp30 interaction has inhibiting
potential. Ergotamine makes 4 hydrophobic bonds, two of which, Asn33 and Pro389, are common
in experimental molecules. Apart from its promising interactions, there is in silico research
claiming that it can be used as a main protease enzyme inhibitor against SARS-CoV-2 as well
(Gurung, Ali et al. 2020).
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Figure 30. (A) 6M0J Structure docked with Ergotamine (B) Binding affinity distribution of 100
iterations (C) Molecular interactions of Ergotamine.

4.4 Conclusion
Due to the challenging nature of drug design and stringent FDA approval process, finding a new
treatment for SARS-CoV-2 in a short period of time is unlikely. Therefore, in this chapter, drugs
that were already approved by the FDA were investigated and molecules that have potential for
inhibiting the spike protein were identified.
First, molecules that exhibited the highest binding affinities towards the spike protein and ACE2
complex were identified. A midsize box containing the RBD was selected, and 1750 FDAapproved drugs were docked with Autodock Vina. The resulting poses were rescored with another
docking tool called Autodock 4.2. Scores from both tools were very similar, which verified our
scoring function. Then, 50 molecules with the highest binding affinity scores were picked, and the
rest of the molecules were discarded.
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The more similar a molecule is to the experimental drugs from Chapter 3, the more likely it is to
inhibit SARS-CoV-2. To verify that our filter created sane results, FDA approved drugs that were
most similar to the experiment drugs were identified. This was done using two computational
methods, molecular fingerprinting and Tanimoto Similarity. Of the top 10 FDA approved drugs
that were most similar to the experimental molecules, 8 of them were in the final 50 list. This
verifies that the initial filter does not act randomly.
Once the list is down to a manageable size, a more detailed analysis was done on the remaining
drug candidates. In order to remove the variance that is caused due to the stochastic nature of the
docking tools, each candidate was docked 100 times. Molecules that target specific places on the
spike protein and ACE2 complex were preferred over the ones that were not consistently binding
to the same place. Molecules which showed high variance in binding location and binding affinity
were eliminated from the list. Interactions of the remaining molecules were analyzed, and
molecules that make bonds with hotspots or with residues that were commonly seen in the analysis
of experimental drugs were picked.
Of the top 10 candidates, 5 of them, Paritaprevir, Glecaprevir, Saquinavir, Simeprevir and
Voxilaprevir, are antivirals. One is an immunosuppressant; one is used to treat bronchitis; one is
used for migraine and two are used for cancer treatment. Most of these drugs are targeted for
relevant diseases. They are either for diseases that affect areas of the body where ACE2 are
expressed, or they are meant to treat virus infections. This is encouraging for in vitro studies.
Another encouraging finding is, one of the molecules from the similarity list (Table 2), Elbasvir,
has been shown to inhibit SARS-CoV-2 in vitro experiments (Milani, Donalisio et al. 2021).
Elbasvir did not show consistent behavior during the iterations and was not considered for the final
list (Figure 31). However, three other molecules from that list, Ergotamine, Saquinavir and
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Paritaprevir showed consistent binding and affinity results and made it to the final list, which we
believe is very promising.

Figure 31. (A) 6M0J Structure docked with Elbasvir (B) Binding affinity distribution of 100
iterations

Binding affinities of the final 10 drugs are similar with the binding affinities of the experimental
drugs, which again is very good. The most promising candidate Voxilaprevir exhibited a binding
affinity of -10.9, which was on par with the top experimental drug, DRI-C91005. Ergotamine had
the lowest affinity of the group with -8.1, which was the same as EryB from the experimental
drugs. The average affinity for the experimental drugs (with the exception of MeBlu) was -9.78
kcal/mol, while the average for the final 10 FDA approved candidates were -9.7 kcal/mol.
The molecules in the final list interacted most commonly with His34, Glu37, Lys417, and Tyr505
hotspot residues. Some of the interactions that were commonly made by the experimental
molecules, Asn33, Arg403 and Pro389, were also frequently exhibited by the final 10 as well.
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Voxilaprevir interacted with 5 hotspots and 2 residues that were common in the experimental drug
interactions. Sirolimus interacted with 2 hotspots and 2 common residues. Cabazitaxel interacted
with one hotspot and one common residue. Simeprevir interacted with 4 hotspots and one common
residue. Saquinavir interacted with 4 hotspots and 2 common residues. Glecaprevir interacted with
3 hotspots and 3 common residues. Irinotecan interacted with 2 hotspots and 1 common residue.
Ergotamine interacted with 1 hotspot and 3 common residues. Paritaprevir interacted with only 1
hotspot. Indacaterol only interacted with 1 hotspot but had 2 common interactions with MeBlu.
Overall, the high number of interactions with both hotspots and residues that were commonly seen
during the analysis of experimental drugs, consistent binding locations, low binding affinities,
other studies that suggest some of the top 10 molecules as treatment candidates, and the
computationally calculated chemical similarity of some of the top 10 molecules to the experimental
drugs suggest that these FDA approved drugs have high potential against SARS-CoV-2.
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Chapter 5 - A Comparative Analysis of the Selected Drug
Repurposing Candidates Against SARS-CoV-2 Variants
Using Molecular Docking Tools
5.1 Introduction
When the viral genome is being replicated, sometimes there are copying errors, and a slightly
different version of the virus is produced. When these changes are favorable for the virus that
particular error, or mutation, makes it to the new generations and the virus genome changes. This
new genome is called a strain. When the mutations change the phenotype of the virus, new strains
are called new variants. The original, standard strain is called the wild type.
Since SARS-CoV-2 is a RNA virus, it has a higher mutation rate than DNA viruses (Lauring and
Andino 2010). When the residues on the surface protein change significantly, the way the virus
functions and avoids the immune system changes too. For example, the A82V mutation of the
Ebola virus has increased its infectiousness and mortality (Diehl, Lin et al. 2016). This makes
SARS-CoV-2 even more of a serious threat. As time passes and SARS-CoV-2 infects more and
more people, new variants are starting to show up too. In this study we will only cover three major
ones, B.1.1.7, B.1.351 and P.1.
The B.1.1.7 variant has spread in the UK first (Volz, Mishra et al. 2021). Eight of the variant
mutations are in the spike protein. The most noteworthy mutations are N501Y in the RBD, and
P681H in the cleavage site. These mutations alter the way the virus binds to ACE2 and replicate.
Especially the N501Y is thought to be increasing the affinity of the spike protein to the ACE2 and
making the virus to be more infectious (Liu, Liu et al. 2021). Another variant with the N501Y
mutation is the B.1.351 variant which was first seen in South Africa. B.1.351 has two other key
mutations in the spike protein, E484K and K417N (Wibmer, Ayres et al. 2021). The third variant,
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P.1, originated in Brazil and has the N501Y mutation as well. It also has the E484K, K417T
mutations in the RBD (Faria, Claro et al. 2021). The RBD mutations that these variants have may
affect how effectively the virus binds to ACE2 and its replication in humans. They may also affect
how effective the experimental drugs can inhibit SARS-CoV-2.
There are currently no approved treatments for the wild type, and this study aims to find drugs that
could be repurposed to treat SARS-CoV-2. However, the mutations in the variants could change
the way SARS-CoV-2 binds to ACE2 and could render possible candidates useless. Therefore, we
have used computational methods to analyze how the mutations might affect the promising FDAapproved drugs from chapter 4.

5.2 Results and Discussion
Variants are created by modifying 6M0J using the PyMol mutagenesis tool. The mutations are
shown in Table 7. The top 10 candidates from the chapter 4 were docked against the variants 100
times each and most common conformations were picked for interaction analysis. Molecular
Interactions of the top 10 candidates for wild type and the variants are shown in Table 8.
Table 7. Amino acid mutations of the variants.

Lineage
B.1.1.7
B.1.351
P.1

•
•
•
•
•
•
•
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Mutations
Asn501  Tyr (N501Y)
Lys417  Thr (K417T)
Glu484  Lys (E484K)
Asn501  Tyr (N501Y)
Lys417  Asn (K417N)
Glu484  Lys (E484K)
Asn501  Tyr (N501Y)

Table 8. Molecular Interactions of the top 10 candidates for wild type and the variants.
Molecule

Type

Binding
Affinity
(kcal/mol)

Voxilaprevir

Wild

-10.9

Asn33(A), His34(A), Asp38(A),
Gln96(A), Lys353(A), Arg403(E),
pi: His34(A), Arg403(E)

B.1.1.7

-9.8

B.1.35
1

-8.4

P.1

-9.6

Asn33(A), Asp38(A), Gln96(A),
Lys353(A), Arg403(E), pi:
His34(A), Arg403(E)
Thr92(A), Gln96(A), Arg403(E),
Asn417(E), Tyr421(E), Tyr505(E)
Halogen: Gln409(E)
Asp30(A), Asn33(A), Asp38(A),
Lys353(A), Arg403(E), pi:
His34(A), Arg403(E)

Wild

-10.4

Thr27(A), His34(A), Lys417(E)

B.1.1.7

-9.6

Glu23(A), Lys417(E)

B.1.35
1
P.1

-9.3

Glu23(A), Tyr421(E)

Wild

-9.3
-10.1

Asp30(A), Tyr421(E)
Ser19(A), Thr27(A), Lys417(E),
Tyr421(E), Tyr473(E), pi: Lys26(A)

B.1.1.7

-9

B.1.35
1

-9.1

P.1

-9.1

Lys31(A), Glu35(A), Lys484(E),
Ser494(E)

Wild

-10

Asn33(A), Gln409(E), Lys417(E)

B.1.1.7

-9.7

B.1.35
1

-9.5

Asn33(A), Gln96(A), Gln409(E),
Lys417(E), Salt Bridge: Arg403(E)
Thr92(A), Gln96(A), Arg403(E),
Asn417(E), Salt Bridge: His34(A)

P.1

-9.4

Sirolimus

Paritaprevir

Cabazitaxel

Hydrogen / pi stacking / Halogen /
Salt Bridge Interactions

Asp30(A), Asn33(A), Lys417(E),
Tyr421(E), Asn460(E)
Lys31(A), Glu35(A), Lys484(E),
Ser494(E)

Asn33(A), Gln96(A), Thr417(E)
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Hydrophobic
Interactions

Lys26(A), Leu29(A),
Asn33(A), Glu37(A),
Phe390(A), Lys417(E),
Tyr453(E)
Lys26(A), Asn33(A),
Glu37(A), Phe390(A),
Lys417(E), Tyr453(E)
Lys26(A), Asp405(E)
Leu29(A), Asn33(A),
Glu37(A), Val93(A),
Phe390(A), Thr417(E),
Tyr453(E)
Asn33(A), Pro389(A),
Asp405(E)
Lys26(A), Asn33(A),
Pro389(A), Asp405(E)
Thr92(A), Leu392(A)
Thr92(A), Leu392(A)
Glu23(A), Lys26(A),
Leu29(A), Val93(A),
Tyr473(E)
Glu23(A), Lys26(A),
Thr27(A), Phe456(E)
Ala71(A), Glu75(A),
Leu79(A), Tyr449(E),
Tyr489(E), Phe490(E)
Ala71(A), Glu75(A),
Leu79(A), Tyr449(E),
Tyr489(E), Phe490(E)
Lys26(A), Asn33(A),
Val93(A), Lys417(E)
Lys26(A), Asn33(A),
Val93(A), Lys417(E)
Leu29(A), Asn33(A),
His34(A), Glu37(A),
Pro389(A), Phe390(A),
Tyr505(E)
Lys26(A), Asn33(A),
Val93(A), Thr417(E)

Simeprevir

Saquinavir

Glecaprevir

Irinotecan

Asp30(A), Asn33(A), Arg393(A),
Lys417(E), Tyr505(E), pi: His34(A)
Lys31(A), Glu35(A), Gln76(A),
Glu484(E), Ser494(E)

Wild

-9.8

B.1.1.7

-8.6

B.1.35
1

-8.6

Gln76(A), Lys484(E), Ser494(E), pi:
Phe72(A)

P.1

-8.6

Gln76(A), Lys484(E), Ser494(E), pi:
Phe72(A)

Wild

-9.7

B.1.1.7

-9.6

Lys26(A), Asp30(A), His34(A),
Arg403(E), Glu406(E), Lys417(E),
pi: His34(A), Salt Bridge: Asp30(A)
Asp30(A), His34(A), Arg403(E),
Glu406(E), Gln409(E), Lys417(E),
Tyr453(E), pi: His34(A)

B.1.35
1

-9.4

Asp30(A), His34(A), Arg403(E),
Glu406(E), Asn417(E), Tyr453(E),
pi: His34(A)

P.1

-9.5

Asp30(A), His34(A), Arg403(E),
Glu406(E), Gln409(E), Thr417(E),
Tyr453(E)

Wild

-9.5

B.1.1.7

-8.4

B.1.35
1

-8.7

Arg393(A), Arg403(E), Arg408(E),
Gln409(E), Lys417(E), Tyr505(E),
Halogen: Asn33(A)
Arg393(A), Gln409(E), Lys417(E),
Tyr505(E), Halogen: Asn33(A),
Tyr505(E)
Glu35(A)

P.1

-8.2

Wild

-9.4

B.1.1.7

-9.1

Arg393(A), Gln409(E), Thr417(E),
Tyr505(E), Halogen: Asn33(A),
Tyr505(E)
Thr27(A), Asn33(A), Arg393(A),
Lys417(E), Tyr473(E)
Arg393(A), Gly504(E), Tyr505(E),
pi: Tyr505(E), Arg403(E), Salt
Bridge: His34(A), Arg403(E)
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Lys26(A), Lys417(E)
Glu35(A), Leu39(A),
Phe72(A), Leu79(A),
Leu452(E), Tyr489(E),
Phe490(E)
Lys31(A), Leu39(A),
Glu75(A), Tyr449(E),
Lys484(E), Tyr489(E),
Phe490(E)
Lys31(A), Glu35(A),
Leu39(A), Glu75(A),
Tyr449(E), Lys484(E),
Tyr489(E), Phe490(E)
Lys26(A), His34(A),
Glu37(A), Val93(A),
Pro389(A), Tyr495(E)
Lys26(A), Asp30(A),
His34(A), Glu37(A),
Val93(A), Pro389(A),
Tyr453(E), Tyr495(E)
Lys26(A), Asp30(A),
His34(A), Glu37(A),
Val93(A), Pro389(A),
Tyr453(E), Tyr495(E)
Lys26(A), His34(A),
Glu37(A), Val93(A),
Pro389(A), Tyr453(E),
Tyr495(E)
Leu29(A), Asp30(A),
Ala387(A), Pro389(A),
Glu406(E)
Leu29(A), Asp30(A),
Asn33(A), Pro389(A),
Glu406(E), Tyr505(E)
Leu39(A), Lys68(A),
Phe72(A), Tyr449(E),
Leu452(E)
Leu29(A), Asn33(A),
Glu406(E), Tyr505(E)
Glu23(A), Lys26(A)
Asn33(A), Pro321(A),
Met383(A), Ala386(A),
Ala387(A), Phe555(A)

Indacaterol

Ergotamine

B.1.35
1

-9.1

P.1

-9.1

Wild

-9.1

Arg393(A), Gly504(E), Tyr505(E),
pi: Tyr505(E), Arg403(E), Salt
Bridge: His34(A), Arg403(E)
Arg393(A), Gly504(E), Tyr505(E),
pi: Tyr505(E), Arg403(E), Salt
Bridge: His34(A), Arg403(E)
Ser47(A), Asp350(A), pi: Trp349(A)

B.1.1.7

-9

Ser47(A), Asp350(A), pi: Trp349(A)

B.1.35
1

-9

Asp350(A), Phe390(A), Arg393(A)

P.1

-9

Asp350(A), Arg393(A), Asn394(A)

Wild

-8.1

Asp30(A), Arg403(E), Tyr505(E)

B.1.1.7

-7.7

Arg403(E), Tyr505(E)

B.1.35
1

-7.8

Arg403(E), Tyr505(E)

P.1

-7.7

Lys26(A), Arg403(E), Tyr505(E)

Asn33(A), Pro321(A),
Met383(A), Ala386(A),
Ala387(A), Phe555(A)
Asn33(A), Pro321(A),
Met383(A), Ala386(A),
Ala387(A), Phe555(A)
Phe40(A), Asp350(A),
Phe390(A), Arg393(A)
Phe40(A), Asp350(A),
Phe390(A), Arg393(A)
Trp69(A), Leu73(A),
Leu100(A), Phe390(A),
Leu391(A), Arg393(A)
Phe40(A), Trp69(A),
Leu73(A), Leu100(A),
Phe390(A), Leu391(A),
Arg393(A)
Leu29(A), Asn33(A),
Val93(A), Pro389(A)
Leu29(A), Val93(A),
Pro389(A)
Leu29(A), Val93(A),
Pro389(A)
Leu29(A), Asn33(A),
Val93(A), Pro389(A)

Voxilaprevir is an anti-viral drug used to treat Hepatitis C. It has the lowest binding affinity to the
wild type (-10.9 kcal/mol). As Figure 32(A) shows, when interacting with the wild type
Voxilaprevir always binds to the same place with the same binding affinity. As Figure 32(B),
32(C), 32(D) show, this changes slightly for the variants. Most of the time Voxilaprevir binds to
the RBD, but in a small number of iterations it binds only to ACE2. While the distance of bonds
with the wild type range between 3-4 Å, they are slightly larger with the variants at 3.5-4 Å. The
interactions that Voxilaprevir makes with B.1.1.7 and P1 are similar, while its interactions with
B.1.351 are different from both the wild type and the two other variants. Voxilaprevir makes
hydrogen bonds with His34, Asp38, Lys353 of the wild type, which are hotspots, as well as with
Asn33 and Arg403, which are common bonds that the experimental molecules make. When
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docked against B 1.1.7 and P.1, it no longer makes a hydrogen bond with the hotspot His34 and
its binding affinity drops to -9.6 kcal/mol range, which is still very good. It keeps the hydrogen
bonds and its pi bonds with His34 and Arg403.
However, Voxilaprevir does not bind with B.1.351 as well as it does with the other variants. Its
binding affinity drops to -8.4 kcal/mol. It makes hydrogen bonds with Arg403 and Tyr505, which
are important residues; but it does not interact with His34 or Lys353. It interacts with Asn417
instead, the mutation that is unique to B.1.351. Lys417 is a hotspot on the wild type, but this
mutation decreases the importance of this residue, which might explain the affinity loss (Pavlova,
Zhang et al. 2021). It might also explain the interaction with Tyr421. Some in silico studies also
suggested that Tyr421 was an important residue (Allam, Ghrifi et al. 2020, Idress and Kumar
2021). However, there is not in vitro or in vivo data to support this claim.
Although Voxilaprevir binds to the RBD with more variance, results suggest that it could still be
effective against the B.1.1.7 and P.1. However, it might not be as effective against B.1.351.
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Figure 32. Binding affinity distributions and overlayed docking poses through 100 iterations of
Voxilaprevir for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Sirolimus is an immunosuppressant agent which consistently binds to the same area of the wild
type with a low affinity (-10.4 kcal/mol). Although its binding affinity increases against the
variants, it keeps making stabile bindings. Sirolimus makes a hydrogen bond with His34 and
Lys417 of the wild type, both of which are hotspots. However, the His34 interaction is not seen
with any of the variants, and Lys417 interaction is only seen with the B.1.17 variant. The binding
affinities and bond distances increase against the variants as well. While bond distances are below
3 Å for the wild type, this number goes up to 4 Å range for the variants and binding affinities
increases about 1 kcal/mol. When Sirolimus is docked against P.1 and B.1.351, it makes a
hydrogen bond with Tyr421. Bonds with this residue are seen when other molecules are docked
against these two variants. Since Sirolimus achieves a decent binding affinity with only two
hydrogen bonds, it is possible that the K417N mutation causes this residue to become more
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important. However, since there is not enough evidence to support this claim, the effectiveness of
Sirolimus against the variants with the K417N mutation is optimistically doubtful.

Figure 33. Binding affinity distributions and overlayed docking poses through 100 iterations of
Sirolimus for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Paritaprevir is an antiviral that is used to treat Hepatitis C. Like the other molecules in our list, it
binds very consistently to the wild type and has a very low binding affinity. When docked against
the variants, Paritaprevir still binds consistently to the same place. However, its binding affinity
increases 1 kcal/mol. The average bond distance with the wild type is around 3 Å. However, this
number goes up to 3.5 Å with B.1.1.7 and to 4 Å with the other variants. Paritaprevir makes a
hydrogen bond with Lys417 of the wild type, which is a hotspot. This interaction exists with
B.1.1.7, but not with B.1.351 and P.1. Instead, when docked against these two variants, it interacts
with Lys484 and Ser494. This is a pattern that we have seen in other drugs as well. When the
Lys417 is mutated to Asn417, the hotspot disappears, and these two residues take over the bonds.
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As covered before Ser494 might have some potential. It is the opposite residue to a hotspot on
ACE2, Arg393. Therefore, Paritaprevir might still be effective against P.1 and B.1.351. However,
it is likely to be effective against B.1.1.7.

Figure 34. Binding affinity distributions and overlayed docking poses through 100 iterations of
Paritaprevir for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Cabazitaxel is a chemotherapeutic agent (Assi, Ibrahim et al. 2020). It binds to the RBD of the
wild type fairly consistently and it has one of the best binding affinities amongst the group (-10
kcal/mol). When docked against the variants, its binding affinity changes slightly, which is
positive. However, while it is somewhat stabile against B.1.1.7, its binding location shows more
variance against the P.1 and B.1.351. Like some other drugs in the list, Cabazitaxel makes a
hydrogen bond with the Lys417 hotspot of the wild type. This interaction is seen across the
variants, even after the Lys417 mutations. This is a positive sign for the effectiveness of the
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molecule against the variants. Also, Cabazitaxel makes almost identical hydrophobic bonds with
all the variants and some of these bonds are with hotspots. This is also another positive sign.

Figure 35. Binding affinity distributions and overlayed docking poses through 100 iterations of
Cabazitaxel for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Simeprevir is the other hepatitis C drug that has been suggested as a SARS-CoV-2 treatment (Li,
Yao et al. 2019, Trezza, Iovinelli et al. 2020). It has one of the lowest binding affinities against the
wild type in this study (-9.8 kcal/mol) and as Figure 36 shows it consistently binds to the same
place. However, when docked against the variants, it binds to 3 or 4 different locations. The most
common conformations are still binding to the receptor binding domain; but the exact location is
different from the location it binds to on the wild type and its binding affinity is significantly
higher. Bond distances increase when docked against the variants as well. While they are in 2.5-3
Å range for the wild type, those numbers increase to 3.5-4 Å range for the variants. Simeprevir
makes hydrogen bonds with Arg393, Lys417, Tyr505, and a pi bond with His34 of the wild type.
These are all hotspots. However, when Simeprevir is docked against the variants it does not make
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these bonds. The interactions for P.1 and B.1.135 are exactly the same; but they are slightly
different from the interactions B.1.1.7 make. Ser494 is a common interaction amongst all variants.
P.1 and B.1.351 make hydrogen bonds with Lys484, while B.1.1.7 makes a hydrogen bond with
Glu484, which is the original residue before the mutation to Lys484. Since Simeprevir binds to
the same area of all three variants, this area might be an active hotspot for the variants. Also,
Ser494 from spike protein RBD normally interacts with Arg393 from the ACE2 and Arg393 is a
hotspot. So, hydrogen bonds with Ser494 can disrupt the ACE2 spike protein bonding and inhibit
the virus. (Choudhary, Malik et al. 2020). These predictions need to be studied further. Although
there is reason for optimism, the variations in the binding locations on the variants need to be
considered as well.

Figure 36. Binding affinity distributions and overlayed docking poses through 100 iterations of
Simeprevir for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.
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Saquinavir is an antiretroviral drug used to treat HIV. It has been suggested as a SARS-CoV-2
remedy in multiple studies (Bello, Martínez-Muñoz et al. 2020, Montenegro, Al-Abed et al. 2020).
It has the most uniform interactions with the wild type and one of the lowest binding affinities (9.7 kcal/mol). It makes hydrogen bonds with important hotspots of the wild type, His34, Arg403,
and Lys417. It behaves more or less the same against the variants as well. Its binding affinity does
not change much. It keeps making hydrogen bonds with His34, Arg403, and the mutated versions
of Lys417. Although it does not make the Asp30 salt bridge with the variants, it makes pi stacking
interactions with B.1.1.7 and B.1.351. It also makes more hydrophobic bonds with the variants.
Also, the distances for its hydrogen bonds barely change and stay around 3 Å. Therefore, it is safe
to say that Saquinavir does not get affected from the mutations.
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Figure 37. Binding affinity distributions and overlayed docking poses through 100 iterations of
Saquinavir for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Glecaprevir is another hepatitis C antiviral drug that binds to the wild type with a low binding
affinity (-9.5 kcal/mol) and it consistently made the same bonds throughout the iterations.
Glecaprevir makes important interactions with the wild type. It makes hydrogen bonds with
Lys417, Tyr505, Arg393, and Arg403, which are all important residues. The average distance for
these bonds is 2.5 Å, which makes this molecule a very promising candidate for the wild type.
However, when docked against the variants, it exhibits a high variance in binding location and
binding affinity. The affinity decreases significantly as well. When the most common
conformations are selected and analyzed, Glecaprevir is still found to be interacting with the
hotspots of B.1.1.7 and P.1, but not B.1.351. The hydrogen bonds it makes with the hotspots
Arg393, Lys417, and Tyr505 of the wild type is carried over to the former variants. Additionally,
these variants make halogen bonds with Asn33 and Tyr505 as well, which might suggest that it
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might still be effective against them. However, Glecaprevir only makes a hydrogen bond with
Glu35 of the B.1.351, which is not a good sign.

Figure 38. Binding affinity distributions and overlayed docking poses through 100 iterations of
Glecaprevir for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Irinotecan is a cancer drug that binds to the wild type with -9.4 kcal/mol affinity. It exhibits
uniform interactions across the iterations. However, this behavior changes when it is docked
against the variants. Although most of the time it still binds to the RBD, sometimes it does not.
The binding affinities against the variants are higher as well; but stable across the variants (-9.1
kcal/mol). The interactions with the variants are exactly the same, which makes this molecule
interesting. Although Irinotecan no longer makes a hydrogen bond with the hotspot Lys417 of the
variants, it makes a hydrogen bond with Tyr505 instead, which is another hotspot. It also keeps its
hydrogen bond with Arg393, another hotspot, across the mutations. Aside from its hydrogen
bonds, it makes pi bonds with Tyr505 and Arg403 of the variants; and salt bridges with His34 and
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Arg403; all of which are hotspots. Although the average bond distance increases by 0.5 Å,
Irinotecan makes more hydrogen, hydrophobic and pi bonds with the variants. When docked
against the variants, it still interacts with hotspots, which suggests that it might be effective against
them as well.

Figure 39. Binding affinity distributions and overlayed docking poses through 100 iterations of
Irinotecan for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Indacaterol is used to treat bronchitis (Cazzola, Calzetta et al. 2014) and unlike the other molecules
in the list, it only binds to ACE2. Since there are other drug candidates that can inhibit SARS-Cov2 by only interacting with ACE2, Indacaterol was added to the final list. In this aspect, it is also
similar to MeBlu from the experimental drugs. As expected Indacaterol does not get affected much
from the mutations. In fact, in some of the 100 iterations it binds to the RBD of the P.1 and B.1.351
variants, which results in lower binding affinities. However, since these are not the common case,
this study will concentrate on the ACE2 only binding poses. While the interactions of Indacaterol
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are exactly the same for the wild type and B.1.1.7, they are slightly different for the other two
variants. When docked against B.1.351 and P.1, Indacaterol makes a hydrogen bond with Arg393,
which is a hotspot. Although it does not make the pi stacking interaction that it does with the wild
type, it makes one extra hydrogen bond in both cases. Also, it makes more hydrophobic bonds as
well. Given all these, Indacaterol is expected to as well or better against the variants.

Figure 40. Binding affinity distributions and overlayed docking poses through 100 iterations of
Indacaterol for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

Ergotamine is a smaller molecule used to treat migraines. When docked against the wild type it
binds consistently to the same place but has a higher binding affinity than the other molecules (8.1 kcal/mol). However, since it only binds to the spike protein and is a smaller molecule, this is
not a big issue. When it is docked against the variants, although it sometimes binds to different
places, majority of the time it still binds to the RDB of the spike protein. Its binding affinity
changes only slightly against the variants as well. Ergotamine makes hydrogen bonds with Arg403
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and Tyr505 of the wild type, both of which are hotspots. These interactions exist with all the
variants, which is very positive. Although the hydrogen bond with Asp30 only exists with the wild
type, Ergotamine still makes most of the hydrophobic bonds with the variants. Therefore, it is
expected to be effective against the variants as well.

Figure 41. Binding affinity distributions and overlayed docking poses through 100 iterations of
Ergotamine for (A) Wild Type, (B) B.1.1.7 Variant (C) B.1.351 Variant, and (D) P.1 Variant.

5.3 Conclusion
Some of the variants we have covered here, or others that will evolve from their lineages might
become the dominant strain at some point. Therefore, when choosing molecules for repurposing,
taking the mutations and variants into account is critical. Of the 10 molecules that were picked in
chapter 4, most lose binding affinity against the new variants, especially B.1.351. Since the K417T
mutation replaces a charged side chain with a polar uncharged one, the affinity of the spike protein
decreases, and this makes it harder for both drug targets and antibodies to bind to the RBD. This
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shows how dangerous the new mutations and variants are. It also casts doubt on the effectiveness
of the current vaccination efforts and shows how important finding a treatment still is.
From the top 10 drugs, Saquinavir performs the best. It consistently binds to RBD, keeps its
interactions with the hotspots across the variants and does not lose much affinity against the
variants. Also, it is an anti-viral which is also a bonus.
Ergotamine and Indacaterol are in the second tier. They still bind to their original binding locations
fairly consistently and do not lose much affinity. Ergotamine interacts mostly with the spike
protein and keeps its hotspots across the variants. On the other hand, Indacaterol only binds to
ACE2, and it does not get affected much from the changes on the spike protein. These two drugs
are also used to treat relevant diseases, which is promising. Paritaprevir is in the next tier. It binds
very consistently and strongly to the wild type. It keeps consistently binding to the same locations
on the variants. However, it loses its hotspot interactions, which is why it is ranked lower.
Voxilaprevir, which performs the best against the wild type and 2 of the variants but does poorly
against B.1.351. Therefore, it needs to be studied further. Another drug that needs further research
is Sirolimus. It binds fairly consistently to the variants. However, its interactions are not common
or studied at all, which makes its performance questionable.
Although Irinotecan and Cabazitaxel binds well to the variants with consistently low affinities,
since they are chemotherapy drugs, they rank lower in the list. If their side effects can be kept
under control, they might be candidates. On the hand Simeprevir and Glecaprevir are not the best
candidates. They lose a high percentage of the affinity against the variants and do not bind
consistently to the same locations on the variants.
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Conclusion
SARS-CoV-2 is a highly contagious and deadly viral disease which has caused a global pandemic.
Despite increasing vaccination rates, it is spreading quickly and affecting our lives deeply. There
are no approved novel treatments yet. Since drug development is a long and time-consuming
process, repurposing an already approved drug would cut down the costs and research time
considerably. Some drugs, like Remdesivir, have already been repurposed to treat the disease.
These drugs mainly try to disrupt the viral replication. They treat the symptoms and decrease the
recovery time but do not decrease the mortality rate or stop the infection.
SARS-CoV-2 virus is made up of 5 major components. The component that is responsible for
infecting the cells is the spike protein. It attaches to ACE2, a protein on the cell membrane, to get
entry to the cell. There are already some experimental molecules that were shown to inhibit the
ACE2 - Spike protein interaction in vitro studies. However, they are in very early stages of the
development. This study aims to identify FDA-approved drugs that behave similar to these
molecules and stop the infection.
1750 FDA drugs were considered as candidates and analyzed with the molecular docking method.
Docking predicts the optimal orientation and position that a molecule would take while making a
bond with another molecule. It also quantifies the strength of the interaction and scores it. A
negative score means that energy would be released when the two molecules make a bond. The
smaller the score is, the more energy gets released, and the bond gets stronger.
The first step in the study was to verify that the docking methodology works as expected.
Experimental molecules were docked against the ACE2-spike protein structure (PDB ID: 6M0J)
using a docking tool called AutoDock Vina. Ligand efficiencies of all the experimental molecules
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were calculated both from simulation results and wet-lab IC50 values. There was an 0.86
correlation between the two sets of the outputs, which showed a strong relationship between the
simulations and wet-lab observations. Next, all of the FDA-approved molecules were docked
against 6M0J using AutoDock Vina. Then results were rescored with another docking tool,
Autodock 4.2, and similar scores were seen. Once scoring was also verified, 50 molecules with
the lowest scores were picked for further analysis.
Since docking is a stochastic process, in order to reduce randomness in the results, the remaining
molecules were docked 100 times. Five criteria were looked at to filter the remaining molecules:
a low binding affinity to the 6M0J, having similar interactions as the experimental molecules,
interacting with hotspot residues on 6M0J, having uniform docking results, and is considered as a
potential treatment in other studies.
Some of the molecules like Elbasvir and Eltrombopag exhibited excellent binding affinities.
However, they also exhibited significant variance in their binding domains during the iterations
and did not always bind to the interface. These were filtered out.
Since the experimental DRI-C, MeBlu, and Ery B molecules were shown to inhibit SARS-CoV-2
in vitro studies, finding drugs that bind to similar places on the combined protein would increase
the chances of success in clinical studies. Molecules like Rifabutin exhibited very small variance
in their binding domain and decent affinity numbers, but shared little to no interactions with the
experimental molecules. These were filtered out as well.
From the remaining molecules, which had decent affinity numbers and uniform binding domain
distributions, 10 that has the most interactions with the hotspot residues (Asp30, Asp38, Glu35,
Glu37, Thr27, Arg393, Lys 31, Lys353, His34 on ACE2 and Arg403, Lys417, Tyr505 on S90

protein) were picked. These top 10 ligands form various hydrogen, hydrophobic, halogen and pi
bonds with the hotspot residues and can potentially inhibit the ACE2 receptor.
From the 10 top drugs, 5 are antiviral/antiretrovirals, one is an immunosuppressant drug; one is
used to treat bronchitis; one is used for migraine, and two are used for cancer
treatment.

Ergotamine, Indacaterol, Paritaprevir, Sirolumis, Irinotecan, Saquinavir, and

Simiprevir exhibited almost the same interactions in every docking iteration. The binding domains
for Cabazitaxel, Voxilaprevir, and Glecaprevir showed a little bit of variance, but not much. All
10 molecules showed similarities with the experimental drugs and interacted with hotspots. Among
the 10, Voxilaprevir exhibited the lowest binding affinity and highest number of interactions with
hotspots. Indacaterol was the only molecule which only interacted with ACE2.
Once the final candidates were determined, their performances against different SARS-CoV-2
variants were studied. Binding affinities of the molecules consistently got worse against the
variants. Some of the molecules no longer made bonds with known hotspots on the S-protein, and
their binding domain variance increased. Mutations to the Lys417(E) were especially critical in
the binding performance. For example, Voxilaprevir, which performed the best against the wild
type, still performed well against the other two variants. But it lost about 1.5 kcal/mol in binding
affinity against the B.1.351 variant, showed greater binding location variance, and could no longer
bind to Asp38(A), His34(A), and Lys353(A) hotspots.
After the performance analysis against the variants, two other molecules, Simeprevir and
Glecaprevir, were filtered out. Two of the remaining molecules, Irinotecan and Cabazitaxel, are
chemotherapy drugs with known side effects. Although they could be used as a final option, their
wide-spread use is not ideal. This brings the list down to 6.
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Saquinavir behaved the most consistently across the variants. It had a decent binding affinity
against all variants and showed little binding location variance against the variants. It interacted
with both ACE2 and spike protein. It made bonds with His34(A), Arg403(E), and Ly417(E)
hotspots. It was also suggested as a SARS-CoV-2 treatment in other publications. Therefore, it
takes the top spot in the list.
Despite its reduced performance against B.1.351, Voxilaprevir, which is an antiviral drug, takes
the second spot. It exhibited the lowest binding affinity scores against three of the four variants. It
made bonds with His34(A), Asp38(A), Lys353(A), and Arg403(E) hotspots. It exhibited fairly low
binding location variance. And it has 3 common interactions with the experimental molecules.
The next molecule in the list is Ergotamine. Although it exhibited a lower binding affinity than the
other molecules in the list, it is also a smaller molecule, like EryB. It has a fairly low binding
location variance across all variants. It made interactions with two hotspots on the spike protein,
Arg403, and Tyr505, and this was consistent for all variants. It was also suggested as a SARSCoV-2 treatment in other in silico studies as well.
The next molecule in the list is Paritaprevir, which is another antiviral drug. Paritaprevir exhibited
low binding affinity scores and a very low binding location variance against all of the variants. It
is also suggested as an RNA polymerase inhibitor against SARS-CoV-2, which is very promising.
It made a high number of interactions with the wild type, one of which, Lys417(E), is a hotspot.
Although it kept a high number of interactions, this hotspot interaction was not seen against the
variants, which is why it is lower on the list.
The next molecule in the list is Indacaterol which is used to treat bronchitis. It exhibited a fairly
high binding affinity score against all the variants and was not affected from the mutations. Unlike
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the other molecules in our list, this molecule binds only to ACE2, which is similar to the
experimental molecule, MeBlu. It made interactions with the hotspot Arg393(A) of all the variants.
Also, another molecule that makes very similar interactions, Catechin, was shown to be effective
against SARS-CoV-2 in vivo experiments.
The last molecule in the list is Sirolimus. Sirolimus binds very consistently to all of the variants
and exhibited decent binding affinity scores across all the variants. However, it did not make as
many interactions as the other molecules in the list. It made bonds with two hotspots, His34(A)
and Lys417(E), on the wild type, but these bonds were not seen with the variants. More
importantly, there is not much research on the interactions it made with the variants. Therefore, it
remains a candidate but requires further research.
This study intends to pave the way for further in vitro and clinical studies of the molecules we
have found to be promising against the SARS-CoV-2 and its variants. Our results suggest that the
binding properties of these molecules make them potential inhibitors for SARS-CoV-2. Of our
final six molecules, three are antivirals, and one is used to treat bronchitis, which is very promising.
Three molecules from the top six scored high chemical similarity scores against the experimental
molecules, which is another positive sign. However, all these molecules need to be researched
further.
Going forward these molecules can be studied further by molecular dynamics. Molecular dynamics
tools simulate the physical movements of molecules over time and can predict whether these
molecules can bind to the spike protein in a stable manner. In parallel, these drugs can be tried
against SARS-CoV-2 and its variants in vitro studies. Cells that express ACE2, active virions, and
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different concentrations of the drugs from the list can be combined, and infection rates can be
recorded. If these tests prove to be successful, further testing can be done in vitro studies.
Even if these molecules fail to inhibit SARS-CoV-2, they are still great reference points for further
de novo drug discovery research. These molecules can be perturbed using generative machine
learning networks such as GANs and resulting molecules can be put through fitness tests till more
effective molecules can be found. In the same manner, an opposite approach can also be taken.
Chemical structures of these molecules can be analyzed, and their sub-structures that interact with
the spike protein can be isolated for bottom to top de novo drug design.
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